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The nonspecific innate immune system fights off infections quickly and further 
controls the development of the highly specialized adaptive immune system for sustained 
protection. Weapons of the innate immune system mainly include pattern recognition 
receptors, leukocytes, complement system, cytokines/chemokines, and antimicrobial 
peptides/proteins including HDPs. Host defense peptides (HDPs) are comprised of a large 
diverse group of small cationic antimicrobial peptides of less than 100 amino acid 
residues adopting an amphipathic conformation. They are widespread in nature and have 
been found in virtually all forms of life.  
 
Based on the structure, HDPs are broadly classified into four major classes: 
including (1) α-helical peptides, (2) β-sheet peptides, (3) peptides with flexible extended 
structures rich in certain amino acids, and (4) peptides with a loop structure. Most HDPs 
are produced by mucosal epithelial and myeloid cells, and processed post-translationally 
to give rise to mature, biologically active peptides. Mature HDPs are capable of killing a 
broad spectrum of pathogens directly by physical disruption of their membranes or by 
interacting with intracellular anionic molecules like DNA, RNA, and proteins.  
Apart from antimicrobial action, HDPs also modulate innate and adaptive 
immunity. Many HDPs have strong capacities to chemoattract different types of immune 
cells, stimulate production of chemokines and cytokines, and promote differentiation and 
maturation of antigen-presenting cells like dendritic cells. HDPs also bind to bacterial 
products thereby neutralizing their ability to stimulate the production of pro-
inflammatory cytokines. Additionally, HDPs limit inflammation by inducing the 
synthesis of anti-inflammatory cytokines such as IL-10 and promoting apoptosis of 
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activated immune cells. With such an array of desirable properties, HDPs have potential 
in the control of infection and inflammation. Because of the cost associated with use of 
synthetic peptides, strategies to stimulate the production of endogenous HDPs may be an 
attractive approach to boost host immunity and enhance disease resistance without 
relying on traditional antibiotics.  
In this dissertation, we have summarized the latest progresses on HDPs regarding 
their classification, structure, and expression as well as their antimicrobial, anti-
inflammatory, and immunomodulatory properties (Chapter II).  In addition, we have 
presented a novel finding on the modulation of chicken HDPs by butyrate, a major short 
chain fatty acid produced by bacterial fermentation of undigested fiber in the intestinal 
tract (Chapter III).  We revealed that butyrate is a potent inducer of many, but not all, 
chicken HDPs both in vitro and in vivo. Remarkably, oral supplementation of butyrate to 
chickens significantly reduced colonization of Salmonella enteritidis in the cecum 
following an experimental infection. We further screened a series of short-, medium-, and 
long-chain fatty acids for their ability to induce chicken HDP gene expression (Chapter 
IV). We found that the aliphatic carbon chain length is largely in an inverse correlation 
with the HDP-inducing activity of fatty acids. Among all fatty acids, short-chain fatty 
acids are the most potent inducers, while medium-chain fatty acids have a moderate 
effect, and long-chain fatty acids are largely ineffective. Importantly, a combination of 
three short-chain fatty acids namely acetate, propionate and butyrate synergistically 
induced HDPs synthesis, resulting in a more pronounced reduction of the S. enteritidis 
load in the chicken cecum. 
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We have further investigated the molecular mechanisms involved in the butyrate-
mediated induction of the avian β-defensin 9 (AvBD9) gene in the chicken (Chapter V). 
We discovered that histone deacetylation is highly beneficial for HDP gene expression, 
as histone deacetylase inhibitors increased AvBD9 synthesis while histone 
acetyltransferase inhibitors reduced butyrate-mediated AvBD9 induction. Notably, JNK 
and p38, but not ERK1/2, MAP kinase pathways are also involved in butyrate-triggered 
AvBD9 expression. Furthermore, activation of cAMP signaling results in an enhanced 
AvBD9 gene expression. Strikingly, a combination of histone deacetylase inhibitor 
(butyrate) and cAMP signaling agonists synergistically augmented AvBD9 induction. 
The results suggested that chicken HDPs synthesis is regulated by a complex mechanism 
involving histone deacetylation and cAMP and MAP kinase signaling pathways.   
Given an urgent need for antibiotic-alternative approaches in disease control and 
prevention, discovery of the molecular mechanisms of HDP gene regulation and an array 
of HDP-inducing agents provide an important first step toward development of novel 
antimicrobial strategies for improvement of animal and human health. 
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1. INTRODUCTION 
 
Host defense peptides (HDPs) are critical effectors of the innate immune system that 
protects the host from harmful pathogens. Being short cationic amphipathic antimicrobial 
peptides, HDPs have been discovered in nearly all forms of life from prokaryotes to 
eukaryotes and from invertebrate to mammalian species. HDPs are widely expressed in 
leukocytes as well as mucosal epithelial cells lining the respiratory, gastrointestinal and 
urogenital systems of the host. They are synthesized as prepropeptides and processed by 
different serine proteases to release mature peptides possessing biological functions. 
They directly kill a myriad of microbes ranging from Gram-positive and Gram-negative 
bacteria to fungi, protozoa, parasites, and enveloped virus. In addition to their direct 
antimicrobial activity, they act as antiinflammatory, wound healing and 
immunomodulatory agents. Because of these unique features, they are being actively 
explored as novel antimicrobials for disease control and prevention. This review 
summarizes structural features, expression patterns, and biological properties of HDPs as 
well as the mechanism of action and gene regulation. Their potential applications in 
animal agriculture and public health were also discussed.   
 
 
2. CLASSIFICATION AND EXPRESSION PATTERN OF HDPs 
 
Innate immunity is an important first line of host defense [1-4]. Invertebrates have 
only innate immune mechanisms, while vertebrates possess both innate and adaptive 
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immunity [1]. Effector components of the innate immune system include natural physical 
barriers like skin and mucosal surfaces, natural microflora, complement system, pattern 
recognition receptors, cytokines, leukocytes, and antimicrobial peptides/proteins [2, 5-8]. 
Antimicrobial peptides/proteins are comprised of peptidoglycan-recognition proteins, 
iron metabolism proteins (lipocalin and lactoferrin), and more importantly, host defense 
peptides (HDPs).  
HDPs are present in virtually all forms of life [1, 9-14]. To date, more than 1,200 
such HDPs have been discovered, and approximately 1,000 are present in eukaryotic 
organisms [15-18]. These peptides generally contain less than 100 amino acid residues 
with an overall net positive charge [19]. Based on their structures, HDPs are broadly 
classified into four major classes including peptides with α-helices, peptides with β-
sheets, peptides adopting flexible structures enriched for certain amino acids like 
arginine, histidine, proline, and tryptophan, and peptides with a loop structure due to the 
presence of a disulfide bond [4, 9, 20-23].  
Cathelicidins and defensins represent two major families of HDPs found in 
vertebrates [24-30]. Cathelicidins were first isolated from bovine neutrophil lysates as 
cyclic dodecapeptides [31]. Since then, cathelicidins have been found in many 
mammalian species as well as in fish, snakes, and birds [32-39]. The name cathelicidin 
was coined from the presence of a highly conserved cathelin domain in the N-terminal 
prosequence of cathelicidins. However, the C-terminal domains of cathelicidins are 
highly variable among species and possess different biological functions (Fig. 1) [5, 34, 
39]. A large group of cathelicidin genes are encoded in the porcine, ovine, and bovine 
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genomes; however, only a single cathelicidin gene exists in dogs, primates, and humans 
[3, 30]. Four cathelicidin genes were found recently in chickens [32, 40].  
Defensins, present in plants, invertebrates, and vertebrates, are rich in cysteines, 
and comprised of 3-4 disulfide bonds forming 3-4 anti-parallel β-sheet structures [41-45]. 
Each vertebrate defensin consists of a signal peptide, proregion and cationic mature 
peptide with six conserved cysteine residues forming three intramolecular disulfide 
bridges creating a “defensin-like” fold with an amphipathic feature [46, 47] (Fig.2). 
Based on the spacing pattern and pairing of cysteine residues, defensins are classified into 
three major subfamilies namely α-, β-, and θ- defensins [45, 47]. The disulfide bridges 
are formed between C1-C6, C2-C4, and C3-C5 for α-defensins, whereas C1-C5, C2-C4, 
and C3-C6 are pairing for β-defensins, and C1-C6, C2-C5 and C3-C4 pairing for θ-
defensins. α- and β-defensins consist of flat triple-stranded β-sheets, while  θ-defensins 
are composed of circular double-stranded β-sheets (Fig. 2) [3, 26, 42, 48-50].  
Cathelicidins and defensins are expressed strategically in leukocytes, skin 
keratinocytes, and mucosal epithelial cells of respiratory, gastrointestinal, and urogenital 
tracts [10, 51]. For example, human cathelicidin LL-37 is mainly found in both 
leukocytes and epithelial cells. While α-defensins and θ-defensins are commonly 
expressed in neutrophils and Paneth cells of the small intestine, the primary source of β-
defensins are mucosal epithelia and skin [24, 52]. HDPs are synthesized as 
prepropeptides, processed posttranslationally by different proteolytic enzymes and stored 
either as propeptides (cathelicidins) or mature peptides (defensins) [53, 54]. Cathelicidins 
are further processed by serine proteases like proteinase 3 in neutrophils and kallikrein 5 
and 7 in the skin in humans [55, 56] and elastase in cattle and pigs [57-59]. α-defensins 
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from intestinal Paneth cells including HD5 and HD6 are processed by metalloproteinase 
7 [2]. 
 
3. ANTIMICROBIAL PROPERITIES OF HDPs 
 
         HDPs are broad-spectrum natural antibiotics that kill or suppress the growth of a 
wide-range of microbes from Gram-positive and Gram-negative bacteria to virus, fungi, 
and parasites [60, 61]. They kill microbes by formation of pores and physical disruption 
of membranes or by inhibition of cellular transcription, translation and/or 
posttranslational machineries [14]. Cationic HDPs initially accumulate onto and 
electrostatically interact with anionic membrane components such as lipopolysaccharide 
of Gram-negative bacteria and lipoteichoic acid of Gram-positive bacteria cell. 
Penetration into negatively charged phospholipids of microbial membranes then takes 
place, resulting in membrane perturbation and leakage of intracellular contents and 
ultimately cell death [13, 62-65]. Because, it is very difficult for microbes to change the 
overall negative charge of their membrane phospholipids, development of resistance 
against HDPs is extremely difficult [65]. Targeted disruption of microbial but not host 
membranes is believed to be due to the difference between prokaryotic and eukaryotic 
cell membranes. While the former is heavily negatively charged with high membrane 
potential (-140 mV), the latter is largely uncharged with a high cholesterol content and 
low membrane potential of approximately -15 mV [22, 66].  
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 The mechanism of pore formation on microbial membranes varies among 
individual HDPs. Depending upon the net charge and spatial structure, HDPs permeate 
membranes via “barrel-stave”, “toroidal-pore”, “molecular electroporation”, “sinking raft 
”, or “carpet-wormhole” mechanism [42, 67-69]. In addition to direct disruption of 
membranes, several HDPs, particularly α- and θ-defensins, suppress viral proliferation by 
acting as collectins. For example, retrocyclins (primate θ-defensins) bind to glycoproteins 
gp41 and gp120 of HIV as well as host CD4 (Cluster of differentiation 4) and prevent 
viral entry by blocking the conformational change of gp41, which is required for 
attachment and fusion of viruses with host cells [70]. Similarly, human neutrophil 
peptides 1, 2, and 3 bind to envelop glycoprotein B (gB) of herpes simplex virus to 
minimize viral entry into the host cells [71].  
 
4. ANTI-INFLAMMATORY EFFECTS OF HDPs 
 
Besides antimicrobial and antiviral properties, HDPs suppress inflammation and 
protect the host from excessive production of proinflammatory mediators triggered by 
microbial products. HDPs are capable of neutralizing bacterial endotoxins, inhibiting 
proinflammatory cytokine production, and inducing antiinflammatory cytokines and 
preventing classical and lectin complement cascades [52, 72]. For example, human 
cathelicidin LL-37 binds and neutralizes LPS and LTA, thereby abolishing the production 
of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. It also stimulates 
antiinflammatory cytokine, IL-10 expression [73]. In a murine infection model, LL-37 
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protects mice from septic shock induced by Pseudomonas aeruginosa [74]. It also 
promotes secondary necrosis of apoptotic neutrophils without causing loss of membrane 
integrity and provoking proinflammatory response of macrophages [75]. Likewise, a 
chicken fowlicidin-1 analog prevents LPS-induced production of nitric oxide and TNF-α 
[76]. Porcine cathelicidin PR-39 inhibits the production of reactive oxygen species while 
bovine myeloid antimicrobial peptide-28 induces apoptosis of activated lymphocytes 
[10]. 
Similar to cathelicidins, defensins also inhibit production of proinflammatory 
cytokines by binding to microbial membranes, surface adhesins, and bacterial toxins and 
neutralizing the ability of their attachment to host cells [77]. For example, human 
neutrophil peptide (HNP) 1 attenuates LPS-mediated production of proinflammatory 
cytokines including IL-1β from monocytes [78]. Human neutrophil peptides 2-3 reduce 
production of several proinflammatory cytokines including IL-1 β, IL-6, IL-8 and TNF- α 
from LPS-stimulated human monocyte-derived macrophages [79].  Human β defensins-3 
also abrogates the induction of IL-6, and TNF-α from human myeloid dendritic cells 
stimulated with Porphyromonas gingivalis [80]. Moreover, there is evidence that 
expression of human α-and β-defensins is reduced in inflammatory diseases like Crohn’s 
disease, emphasizing the role of defensins in regulation of inflammation [56, 81].  
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5. IMMUNOMODULATION OF HOST IMMUNITY BY HDPs 
 
HDPs have capacity to directly kill pathogens, but their antimicrobial activity is 
often diminished by the monovalent and divalent cations, serum, and polyanionic 
molecules like glycosaminoglycans present in the biological fluids [82]. In fact, HDPs 
may not always have a direct antimicrobial action under physiological conditions. 
However, they still protect the host from infections [10, 14, 83]. For example, 
cathelicidin LL-37 protects mice from Gram-positive bacteria when administered 
exogenously but cannot inhibit bacterial growth in tissue culture medium containing 
physiologically similar salt concentrations [82], implying its role in immunomodulation.  
HDPs promote diverse immunomodulatory functions by acting as 
chemoattractants, by stimulating the production of chemokines and cytokines, and by 
regulating complement activation and promoting wound healing (Fig. 3 )[30, 49, 84]. For 
example, Human β defensin (HBD) 1 and HBD3 chemoattract immature dendritic cells 
and memory T-cells while human α-defensins are chemotactic to naïve T cells [53]. 
Similarly, HNP1-3 and HBD3-4 stimulate migration of neutrophils and monocytes, 
whereas LL-7 and HNP1-3 are chemotactic to mast cells and induce degranulation to 
release histamine and prostaglandin 2 respectively [53].  HDPs induce production of 
various pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6 as well as 
chemokines such as IL-8 and monocyte chemotactic protein-1 from mononuclear 
phagocytes and epithelial cells [53, 85]. 
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In addition to modulation of host immunity, HDPs appear to be promising wound 
healing agents. HDPs promote re-epithelialization, angiogenesis and vascularization by 
inducing proliferation of epithelial cells and vascular endothelial cells and 
chemoattracting fibroblasts and macrophages [3]. HDPs enhance synthesis of growth 
factors and cytokines in keratinocytes and epithelial cells that are essential for wound 
repair [14]. For example, human LL-37 and HBDs enhances IL-18 secretion from 
keratinocytes [86] that is involved in angiogenesis process [87]. Porcine PR-39 is 
involved in wound healing by increasing the expression of extracellular matrix 
proteoglycans syndecan-1 and 4, which are important for activation of many growth 
factors [88]. HBD-2 and 3 are also shown active involvement in re-epithelialization of 
damaged skin [89]. Given such an array of immunomodulatory properties of HDPs, it is 
highly desirable to harness these properties for antimicrobial therapies to boost host 
immunity without directly acting on microbes, thereby minimizing the risk of developing 
resistance [90].  
 
6. TRANSCRIPTIONAL MODULATION OF HDP EXPRESSION 
 
 Many HDPs expression is inducible in response to infection. Human cathelicidin 
LL-37 expression is induced in response to gram negative bacteria such as Salmonella 
enterica serovar Dublin, and enteroinvasive Escherichia coli in human colonic 
epithelium [91], Helicobacter pylori in human gastric epithelial cells [92] and 
Pseudomonas aeruginosa in corneal epithelium [93] and Gram-positive bacteria 
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including S. aureus in keratinocytes [94], Mycobacterium species in human alveolar 
macrophages, monocytes, neutrophils and epithelial cells [95, 96], bacterial products 
(LPS and LTA) in sinus epithelial cells [97], flagellin in corneal epithelial cells [93]. On 
the other hand, Shigella dysenteriae, Vibrio cholera [98] and Nisseria gonorrhoeae [99] 
downregulate LL-37 expression in intestinal epithelial cells. 
In addition, stressors like injury [100], endoplasmic reticulum stress [101], and 
inflammatory disorders [102] also enhance LL-37 expression in keratinocytes. Moreover, 
various proinflammatory cytokines (IL-1α, IL-6, and IL-17) [103-105] and growth 
factors [insulin like growth factor-1, transforming growth factor (TGF)-α and TGF-β1] 
[106] promote LL-37 expression in skin epithelial cells while proinflammatory cytokines 
display no effect on colonic epithelium [91]. IL-10 and IL-13 also mitigate LL-37 
expression in the skin [5], and IL-18 stimulates LL-37 expression in colonic epithelial 
cells [107] .   
Apart from infection and stress, human LL-37 expression is also induced by 
several dietary factors including short-chain fatty acids, flavones, zinc, and vitamin D3. 
For example, short-chain fatty acids including butyrate and propionate induce LL-37 
expression in intestinal and hepatic cells as well as lung epithelial cells by acting as 
histone deacetylase (HDAC) inhibitors [108-110]. Other HDAC inhibitors including 
phenylbutyrate and trichostatin (TSA) are also able to augment LL-37 expression in 
epithelial and monocytic cells [108, 110, 111]. Furthermore, oral supplementation of 
rabbits with butyrate or phenylbutyrate has shown reduced dysentery symptoms in 
Shigellosis infections through upregulation of rabbit cathelicidins in colon and lung 
epithelia [112, 113]. In animal agriculture, particularly in poultry, organic acids including 
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butyrate and propionate have been used for decades and shown an overall improved 
resistance to S. enteritidis [114] and Clostridium perfringens [115]. Many antibacterial 
mechanisms of organic acids have been proposed, including a reduction of intestinal pH, 
direct antibacterial activities, and suppression of bacterial attachment to host intestinal 
cells [114, 116-118]. It is also possible that organic acids, particularly short-chain fatty 
acids, enhance disease resistance by inducing HDP gene expression.  
Besides fatty acids, vitamin D3 stimulates LL-37 synthesis in lung epithelial cells, 
keratinocytes, and monocytes, but not in colon epithelial cells [119-122]. LL-37 
expression is also augmented by various cAMP analogs and agonists in mucosal 
epithelial cells [123]. In addition, zinc has the capacity to enhance LL-37 expression in 
human Caco-2 intestinal epithelial cells [124]. In humans, probiotic E. coli enhances 
human beta defensin synthesis [125]. Likewise, several probiotics and prebiotics have 
been used to control infections and inflammatory disorders like inflammatory bowel 
disease and irritable bowel syndrome [126]. It is likely that probiotics and prebiotics 
stimulate bacterial fermentation of short-chain fatty acids, which in turn promote HDP 
synthesis, host immunity, and disease resistance.  
 
7. MOLECULAR MECHANISMS OF HDP MODULATION 
 
The regulatory mechanisms involved in cathelicidin gene expression are very complex. 
Histone acetylation and the signaling pathways mediated by mitogen-activated protein 
(MAP) kinases, cAMP, vitamin D receptor (VDR), and NF-κB are all capable of 
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transactivating HDP gene expression. In some cases, the pathways cross-talk with each 
other, leading to a synergistic induction of HDP synthesis. Short-chain fatty acids and 
HDAC inhibitors induce human LL-37 gene expression primarily through histone 
hyperaceylation of the gene promoter and also global core histone acetylation [108, 109, 
121]. Three classic MAP kinase (p38, JNK, and ERK1/2) pathways, but not NF-κB, are 
involved in most epithelial cells in HDAC inhibitor-mediated induction of LL-37 
expression [109]. Vitamin D3 enhances LL-37 expression in keratinocytes through 
activation of VDR, which in turn binds to vitamin D response element (VDRE) on the 
promoter [60, 119, 127, 128].  Additionally, vitamin D3 induces LL-37 expression 
through activation of PPARγ, resulting in activation of p38 MAP kinase pathway and 
binding of transcription factor AP-1 to the gene promoter [129]. cAMP signaling agonists 
were recently found to turn on LL-37 gene expression by activation of the protein kinase 
A (PKA) pathway, which ultimately leads to phosphorylation of cAMP response element 
binding protein (CREB) and AP-1 and gene transactivation [123].  
In psoriatic skin, overexpressed LL-37 binds to self-DNA to turn on TLR9-
dependent signaling pathway, leading to excessive inflammation and psoriasis [5, 103, 
105]. TLR2 agonists also increase the expression of the genes for CYP27B1 and VDR. 
CYP27B1 further convert inactive vitamin D3 to 1, 25-vitamin D3, which leads to LL-37 
upregulation via VDR activation [127, 128]. Bacteria, bacterial products, and 
proinflammatory cytokines activate HDP gene expression primarily through Toll-like 
receptor-mediated NF-κB activation, although MAP kinase pathways are also activated in 
most cases [105,130-132,133,134,135].  Zinc regulates LL-37 expression in epithelial 
cells through p38 and ERK1/2 MAP kinase pathways [124]. 
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A synergist effect on HDP gene induction has been demonstrated with HDAC 
inhibitors, VDR and cAMP signaling. For example, butyrate and vitamin D3 synergize 
with each other in inducing LL-37 expression in keratinocytes through activation of 
SRC3, which has inherent histone acetyltransferase activity [121]. Butyrate also 
synergizes with forskolin, a cAMP agonist, in inducing LL-37 expression through 
prolonged activation of CREB [123].   
In summary, HDPs possess a myriad of beneficial functions with potent 
antimicrobial, anti-inflammatory, and immunomodulatory activities.  A growing body of 
evidence suggests that dietary factors including vitamin D3, short-chain fatty acids, zinc, 
and certain amino acids are capable of inducing HDP synthesis in humans. Convenient 
dietary modulation of the endogenous HDP synthesis may have potential to be explored 
as a novel antibiotic-free strategy to disease prevention and control for both animal and 
human health. We have explored the potential and found that short-chain fatty acids and 
their structural and functional analogs are strong inducers of HDP production, with the 
capacity to enhance innate immunity and disease resistance in chickens. 
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FIGURE AND FIGURE LEGENDS 
 
 
Fig. 1. Structure and functional domains of defensins and cathelicidins. SP: Signal 
peptide, AMP: mature antimicrobial peptide. Figure was adopted from reference [5]. 
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Fig. 2. Linkage of disulfide bonds and spatial structures of mammalian defensins. 
Figure was adapted from reference [26].  
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Fig. 3. Biological functions of host defense peptides (HDPs). HDPs simultaneously 
possess direct antimicrobial, immunomodulatory, anti-inflammatory, and wound healing 
activities. Figure was adopted from reference [14]. 
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ABSTRACT 
 
Host defense peptides (HDPs) constitute a large group of natural broad-spectrum 
antimicrobials and an important first line of immunity in virtually all forms of life. 
Specific augmentation of synthesis of endogenous HDPs may represent a promising 
antibiotic-alternative approach to disease control. In this study, we tested the hypothesis 
that exogenous administration of butyrate, a major type of short-chain fatty acids derived 
from bacterial fermentation of undigested dietary fiber, is capable of inducing HDPs and 
enhancing disease resistance in chickens. We have found that butyrate is a potent inducer 
of several, but not all, chicken HDPs in HD11 macrophages as well as in primary 
monocytes, bone marrow cells, and jejunal and cecal explants. In addition, butyrate 
treatment enhanced the antibacterial activity of chicken monocytes against Salmonella 
enteritidis, with a minimum impact on inflammatory cytokine production, phagocytosis, 
and oxidative burst capacities of the cells. Furthermore, feed supplementation with 0.1% 
butyrate led to a significant increase in HDP gene expression in the intestinal tract of 
chickens. More importantly, such a feeding strategy resulted in a nearly 10-fold reduction 
in the bacterial titer in the cecum following experimental infections with S. enteritidis. 
Collectively, the results indicated that butyrate-induced synthesis of endogenous HDPs is 
a phylogenetically conserved mechanism of innate host defense shared by mammals and 
aves and that dietary supplementation of butyrate has potential for further development as 
a convenient antibiotic-alternative strategy to enhance host innate immunity and disease 
resistance.  
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1. INTRODUCTION 
 
Host defense peptides (HDPs), also known as antimicrobial peptides, are present 
in virtually all species of life and constitute a critical component of the innate immunity 
[2-6]. Defensins and cathelicidins represent two major families of HDPs in vertebrates 
[7-12]. While defensins are categorized by the presence of six conserved cysteine 
residues in the C-terminal mature sequence [7-9, 12], all cathelicidins consist of a 
conserved cathelin domain in the pro-sequence with a highly diversified C-terminal 
mature sequence [10, 11]. The chicken genome was recently found to encode a total of 14 
β-defensins known as AvBD1-14 [13-15] and four cathelicidins, namely fowlicidins 1-3 
[13, 16, 17] and cathelicidin-B1 [18]. All AvBDs are densely clustered on chicken 
chromosome 3q [14, 15], whereas cathelicidin genes are located on chromosome 2p [17, 
18]. Both chicken AvBDs and cathelicidins are expressed in a wide range of tissues, with 
cathelicidins expressed most abundantly in the bone marrow or bursa of Fabricius [16-18] 
and β-defensins in the liver and throughout the digestive, respiratory, and reproductive 
tracts [13, 15]. HDPs possess broad-spectrum antimicrobial activities against bacteria, 
protozoa, enveloped virus, and fungi mainly through direct binding and lysis of microbial 
membranes [6, 19]. 
Because of such physical interactions, it is extremely difficult for pathogens to 
develop resistance to HDPs. Many chicken HDPs such as AvBD9 (formally known as 
gallinacin-6) and cathelicidin B1 have been found to possess potent antibacterial 
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activities against a broad range of bacteria including Salmonella [17, 20-26]. Besides 
direct microbicidal activities, HDPs have a strong capacity to modulate the innate 
immune response by inducing chemotaxis and activation of various types of leukocytes 
[3, 5]. Because of these pleiotropic effects, HDPs have been actively explored as a new 
class of therapeutic agents against antibiotic-resistant microbes and other inflammatory 
diseases [3, 6].   
Butyrate, a major species of short-chain fatty acids produced by bacterial 
fermentation of undigested carbohydrates in the intestine [27, 28], was recently found to 
be capable of inducing HDP expression in humans and rabbits [29-31]. To test whether 
butyrate can augment HDP gene expression in a non-mammalian species, we studied the 
effect of butyrate on HDP gene expression and the antibacterial activity of monocytes in 
the chicken. Furthermore, we examined the effect of supplementing butyrate in the feed 
on the titer of Salmonella enteritidis in the cecum following experimental infections. We 
concluded that butyrate-mediated induction of HDP synthesis is phylogenetically 
conserved in both mammals and aves. Additionally, butyrate may be further exploited as 
a cost-effective feed or food additive in enhancing host immunity and disease resistance.  
 
2. MATERIALS AND METHODS 
 
2.1. Isolation, culture, and stimulation of chicken cells and intestinal tissue explants 
Chicken HD11 macrophage cells [32] were cultured in complete RPMI 1640 containing 
10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin, and 
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seeded at 2 × 106 cells/well in 6-well cell culture plates overnight, prior to stimulation 
with different concentrations of sodium butyrate (Sigma) in duplicate and incubated at 
37oC and 5% CO2 for indicated times. Chicken peripheral blood mononuclear cells 
(PBMCs) were isolated from EDTA-anticoagulated venous blood of adult layers through 
gradient centrifugation using Histopaque 1077 (Sigma). Monocytes were obtained by 
seeding PBMCs at 3 × 107 cells/well in 6-well plates overnight and washing off non-
adherent cells twice with calcium- and magnesium-free Hank’s balanced salt solution 
(HBSS). Monocytes were replenished with fresh complete RPMI 1640 prior to 
stimulation with sodium butyrate. Bone marrow cells were collected from femur bones of 
1- to 2-week-old broiler chickens, lysed of erythrocytes, and cultured at 1 × 107 cells in 
60-mm tissue culture dishes in RPMI 1640 containing 20 mM HEPES, 10% FBS, 100 
U/ml penicillin, and 100 µg/ml streptomycin, followed by butyrate stimulation.  
Jejunal and cecal explants were obtained by washing thoroughly a segment of the 
jejunum and cecum of 1- to 2- week-old broiler chickens with cold HBSS containing 50 
µg/ml of gentamicin, followed by slicing in a series of 0.5-cm long segments and placing 
individually in 6-well tissue culture plates in RPMI 1640 containing 20 mM HEPES, 
10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µg/ml gentamicin. 
Jejunal and cecal explants were cultured at 37oC and 5% CO2 in the presence of different 
concentrations of sodium butyrate in duplicate for 24 h.  
2.2. Real-time RT-PCR analysis of chicken HDP gene expression  
Following treatment with sodium butyrate, chicken cells and tissue explants were lysed in 
Tri Reagent (Sigma) for extraction of total RNA. The first-strand cDNA was synthesized 
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from 300 ng of total RNA using QuantiTect Reverse Transcription Kit (Qiagen) in a total 
volume of 4 µl. Real-time PCR was then performed using QuantiTect SYBR Green PCR 
kit (Qiagen) and MyiQ Real-Time PCR Detection System (Bio-Rad) in 10 µl reactions 
containing 1/40 or 1/20 of the first-strand cDNA and gene-specific primers for 14 AvBDs 
(Table 1), 4 chicken cathelicidins, multiple cytokines and GAPDH (Table 2) as described 
[17, 26, 33]. PCR cycling conditions were 95oC for 10 min, followed by 45 cycles of 
94oC for 15 sec, 55oC for 20 sec, and 72oC for 30 sec. The specificity of PCR reaction 
was confirmed by the melt curve analysis. The gene expression levels were quantified 
using the comparative ∆∆Ct method with the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene as a reference for normalization. 
2.3. Cell cytotoxicity of butyrate in HD11 cells 
The cytotoxicity assay was performed as described previously [26, 33, 34]. Briefly, 
HD11 cells (1 × 105) were seeded overnight in 96-well tissue culture plates. Butyrate was 
added in duplicate from 0 to 16 mM for 18 h, following by addition of 10% of 
alamarBlue (Invitrgoen) for another 6 h. The fluorescence was read at 545 nm excitation 
and 590 nm emission. Cell death (%) was calculated as [1 – (Fbutyrate –  Fbackground)/(Fcontrol 
– Fbackground)]  × 100, where Fbutyrate is the fluorescence of cells exposed to different 
concentrations of butyrate, Fcontrol is the fluorescence of cells only, and Fbackground is the 
background fluorescence of 10% alamarBlue in cell culture medium without cells.  
2.4. Antibacterial activity of monocytes treated with butyrate 
Following overnight adherence of PBMCs to cell culture dishes, chicken monocytes were 
replenished with fresh antibiotic-free RPMI 1640 and incubated with 0, 0.5, 1, 2, and 4 
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mM of sodium butyrate for 24 h. Cells were then scraped, stored at -80oC overnight, 
lysed with 1% Triton X-100, and centrifuged at 12,000 × g for 10 min at 4oC. Serial 2-
fold dilutions were then prepared from the cell supernatants and incubated with 2 × 104 
CFU of Salmonella enteritidis (ATCC 13076) in 20% Trypticase Soy Broth containing 1 
mM NaH2PO4 and 25 mM NaHCO3 for 9 h in a 96-well plate at 37oC as described [35]. 
Bacterial turbidity was measured at OD590 nm using an ELISA plate reader. Different 
concentrations of sodium butyrate were also directly added to S. enteritidis in the same 
growth medium to measure turbidity after 9 h incubation.   
2.5. Phagocytosis assay of HD11 cells 
Phagocytosis of S. enteritidis phage type 13a by HD11 cells was measured as described 
with slight modifications [36]. After seeding 6 × 106 cells in complete RPMI 1640 
overnight in 60- mm tissue culture plates, HD11 cells were stimulated with and without 
0.5, 1 or 2 mM sodium butyrate for 24 h. Cells (2.5 × 106) were then incubated with 2.5 × 
107 CFU of S. enteritidis phage type 13a in 1 ml RPMI 1640 containing 5% chicken 
serum for 30 min at 37oC. To kill extracellular bacteria, cells were washed twice with ice-
cold HBSS, re-suspended with 1ml RPMI 1640 containing 100 µg/ml gentamicin for 1 h 
at 37oC. Cells were then lysed by incubating with 1% Triton X-100 for 15 min, serially 
diluted, and spread on Brilliant Green agar plates (Becton Dickinson) containing 20 
µg/ml of nalidixic acid and incubated overnight at 37oC for enumeration.   
2.6. Oxidative burst assay of HD11 cells 
The assay of oxidative burst activity was performed as previously described  with slight 
modifications [37]. Briefly, HD11 cells were seeded at 1 × 105 cells in a 96-well plate in 
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complete RPMI 1640 and cultured overnight. After addition of 0, 0.5, 1, and 2 mM of 
sodium butyrate for 24 h, cells were washed with HBSS to remove antibiotics, 
replenished with fresh RPMI 1640 free of Phenol Red and antibiotics, and rested for 30 
min. Phorbol 12-myristate 13-acetate (PMA, Sigma) and 2’,7’-
dichlorodihydrofluorescein diacetate (DCFDA, Sigma) were added to cells to final 
concentrations of 0.5 µg/ml and 10 µM, respectively.  The fluorescence was monitored at 
485 nm excitation and 528 nm emission using FLx800 Multi-Detection Microplate 
Reader (Bio-Tek Instruments) 1 h after incubation at 37oC. The results were normalized 
against protein concentrations, which were measured using the Bradford assay (Bio-Rad) 
as per manufacturer’s instructions. 
2.7. Flow cytometric analysis of MHC class I and II surface markers 
Following stimulation with 4 mM butyrate, 1 µg/ml LPS from E. coli O111:B4 (Sigma) 
or left untreated for 24 h, HD11 cells were scraped, washed, and adjusted to 1 × 106/ml 
with the FACS buffer (0.1% BSA +  0.02% sodium azide in phosphate buffered saline). 
Cells were preincubated in the FACS buffer containing 1% chicken serum and 1% of rat 
FCγ III/II receptor blocker (clone 2.4G2, eBioscience) for 15 min, followed by 
incubation with fluorescein isothiocyanate (FITC)-conjugated mouse anti-chicken MHC 
class I (clone F21-2, SouthernBiotech) and R-phycoerythrin (R-PE)-conjugated mouse 
anti-chicken MHC class II (clone 2G11, SouthernBiotech) monoclonal antibodies for 
another 30 min. Flow cytometry was performed on a FACSCalibur Flow Cytometer 
(Becton-Dickinson) and analyzed with BD CellQuest Pro-software. 
2.8. Butyrate feeding and S. enteritidis infection of chickens 
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Two chicken trials were conducted to test the in vivo effect of butyrate on HDP gene 
expression and disease resistance. In trial 1, a total of 20, five-day-old male Cornish Rock 
broiler chickens (Ideal Poultry, Cameron, TX) were equally divided and fed with a 
standard antibiotic-free ration mixed with or without 0.2% sodium butyrate for 48 h prior 
to intraesophageal infections with 0.5 ml of Lysogeny broth ( LB) containing 1 × 106 
CFU of S. enteritidis phage type 13a [38]. After continuous feeding with butyrate-
supplemented feed for another 4 days, the birds were euthanized and cecal contents were 
aseptically collected from each animal, serially diluted in PBS, and plated on Brilliant 
Green agar plates (Becton Dickinson) containing 20 µg/ml of nalidixic acid for bacterial 
enumeration. Trial 2 was conducted similarly with a total of 30, five-day-old male 
broilers fed with or without 0.1% or 0.2% sodium butyrate supplementation in the feed 
for two days, with 10 chickens per treatment. An intraesophageal infection with 1 × 106 
CFU of S. enteritidis phage type 13a was conducted 2 days later and butyrate 
supplementation was continued for another 4 days. Cecal contents were then collected 
from each chicken for bacterial counting. All animal procedures were approved by the 
Institutional Care and Use Committee of Oklahoma State University.  Unpaired Student’s 
t-test was performed among groups, and p < 0.05 was considered statistically significant. 
 
3. RESULTS 
 
3.1. Butyrate induces HDP gene expression in chicken HD11 macrophage cells, 
primary monocytes, bone marrow cells, and jejunal and cecal explants 
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To elucidate the effect of butyrate on HDP gene expression in the chicken, we 
first stimulated HD11 macrophage cells and primary chicken monocytes with different 
concentrations of sodium butyrate for various times, followed by real-time RT-PCR 
analysis of the expressions of the genes for all 14 AvBDs  and 4 cathelicidins.  Butyrate 
enhanced HDP gene expression significantly in all chicken cell types tested (Fig. 1). The 
avian β-defensin 9 (AvBD9) gene was dramatically induced in HD11 cells in a time-
dependent manner peaking at 24-48 h following stimulation with 4 mM butyrate (Fig. 
1A). A dose-dependent induction was also evident in HD11 cells, with 4 mM butyrate 
giving nearly 5400-fold induction of AvBD9 after treatment for 24 h (Fig. 1B). Similarly, 
the AvBD9 gene expression was dose-dependently augmented in primary monocytes, 
resulting in a 200- and 650-fold increase following 24 h stimulation with 4 and 8 mM 
butyrate, respectively (Fig. 1C). A 700-fold augmentation of the AvBD9 gene was also 
observed in chicken bone marrow cells treated with 4 mM butyrate for 24 h (Fig. 1D). It 
is noteworthy that the kinetics of butyrate-mediated HDP gene expression is similar in 
humans, where a peak response occurred in intestinal cell lines 1-2 days following 
treatment with 4 mM butyrate [30, 31]. However, it is not clear why the sensitivity of the 
two chicken cell types to butyrate differs. Butyrate at 4 mM gave an optimal induction of 
the AvBD9 gene in HD11 and bone marrow cells, whereas a peak response occurred at 8 
mM in primary monocytes, although no appreciable impact on the viability of the cells 
was observed in any cell type in response to up to 8 mM butyrate (data not shown).  
Besides AvBD9, several other chicken HDP genes including cathelicidin B1, 
AvBD3, AvBD4, AvBD8, AvBD10, and AvBD14, also showed largely dose-dependent 
inductions in response to butyrate treatment in HD11 cells, albeit at a lesser magnitude 
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than AvBD9 (Fig. 2). A similar trend also occurred in chicken primary monocytes, where 
butyrate triggered dose- dependent up-regulation of cathelicidin B1, AvBD3, AvBD5, and 
AvBD14 (Fig. 2). Notably, a subset of HDP genes including AvBD1, AvBD6, and 
fowlicidins 1-3 were essentially not modulated by butyrate in either cell type (Fig. 2). 
Furthermore, AvBD2 and AvBD7 were even slightly down-regulated in primary 
monocytes and HD11 cells, respectively (Fig. 2), suggesting differential regulation of 
HDPs by butyrate.  To further examine whether butyrate is capable of augmenting HDP 
gene expression in intestinal cells, chicken jejunal and cecal explants were prepared and 
stimulated with butyrate for 24 h. Three representative HDPs, namely AvBD9, AvBD14, 
and cathelicidin B1, were induced significantly in a dose-dependent manner in both the 
jejunum (Fig. 3A) and cecum (Fig. 3B), although the magnitude of induction was 
generally less pronounced in the cecum than in the jejunum.   
To confirm the HDP-inducing activity of butyrate in vivo, we fed 2-day-old 
broiler chickens with and without 0.1% and 0.2% butyrate in standard ration for 2 days 
and harvested the crop, cecal tonsil, and cecum for real-time RT-PCR analysis of the 
AvBD9 gene expression. As shown in Fig. 4, significantly induced AvBD9 expression 
was observed in the crop, with 0.1% and 0.2% butyrate leading to 22- and 7.5-fold 
increase, respectively. A similar, but less dramatic trend also occurred in the cecal tonsil 
and cecum (Fig. 4). It is not known why a reduced response was seen with 0.2% butyrate 
supplementation compared to 0.1% butyrate. Perhaps higher concentrations of butyrate 
are more potent in inducing growth arrest and apoptosis [27, 28]. The finding that 
AvBD9 induction is more pronounced in the crop than in the lower digestive tract is 
perhaps related to tissue specificity. However, it is more likely because local 
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concentrations of supplemented butyrate are much higher in the crop than in other parts 
of the intestinal tract, similar to earlier findings that the majority of butyrate is absorbed 
in the crop before reaching the lower digestive tract [39, 40]. Collectively, these results 
strongly suggest that butyrate is a potent inducer of the chicken HDP expression in 
multiple cell types both in vivo and in vitro, although cell- and tissue-specific induction 
patterns are also evident.  
3.2. Butyrate triggers no or minimum inflammatory response 
Butyrate generally exerts anti-inflammatory effects and has been used to treat 
inflammatory bowel diseases [27, 28]. To confirm butyrate-mediated specific 
augmentation of HDP gene expression without triggering a proinflammatory response, 
we treated HD11 cells with and without butyrate for 3 and 24 h and analyzed the 
expressions of three representative cytokines, namely IL-1β, IL-8, and IL-12p40. 
Butyrate had essentially no effect on either IL-1β (Fig. 5A) or IL-12p40 expression (Fig. 
5B) at both time points. No influence on IL-8 expression was observed after 3 h 
stimulation with a moderate induction only after 24 h (Fig. 5C). In contrast, IL-1β, IL-8, 
and IL-12p40 were induced markedly in response to 1 µg/ml LPS (Fig. 5). These results 
demonstrated that butyrate selectively induces HDPs with a minimum impact on 
proinflammatory cytokine expression, consistent with earlier transcriptional profiling 
results that butyrate is generally anti-inflammatory, suppressing expression of certain 
cytokines with no effect on the majority of them [41, 42].  
3.3. Butyrate augments the antibacterial activity of chicken monocytes through 
induction of HDPs 
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To investigate the functional consequence of butyrate-induced HDP expression, 
we stimulated chicken primary monocytes with and without different concentrations of 
butyrate for 24 h, lysed cells, incubated cell lysates with S. enteritidis, and measured 
bacterial turbidity after 9 h. As shown in Fig. 6, a dose-dependent, statistically significant 
suppression of bacterial growth in butyrate-treated monocyte lysates was observed, with 
4 mM butyrate giving greater than 3-fold reduction in turbidity. It is worth noting that 
incubation of bacteria with butyrate alone had no impact on bacterial growth at up to 4 
mM (Fig. 6), implying that butyrate is incapable of killing bacteria directly at the HDP-
inducing concentrations. Furthermore, given that butyrate in the cell culture medium was 
completely washed off prior to cell lysis and the antibacterial assay, an enhancement in 
the antibacterial activity of the cell lysates is unlikely due to the direct bacterial killing 
activity of butyrate.  
To further rule out the possibility that butyrate-induced augmentation of the 
antibacterial activity was not attributed to a change in phagocytosis of chicken 
macrophages by butyrate, we first incubated HD11 cells with different concentrations of 
butyrate for 24 h and then measured the phagocytic capacity of the cells to S. enteritidis. 
In comparison with non-treated cells, essentially no difference in phagocytosis was 
observed with any concentration of butyrate (Fig. 7A). We further examined the 
influence of butyrate on the oxidative burst activity of chicken macrophages. As seen in 
Fig. 7B, PMA triggered a significant oxidative burst in HD11 cells; however, butyrate 
had a minimum impact on the cells treated with and without PMA.   
To test whether butyrate is capable of activating chicken macrophages, we 
quantified a surface marker of cell activation, i.e., MHC class II, on HD11 cells by flow 
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cytometry following stimulation with 4 mM butyrate for 24 h, using MHC class I as a 
house-keeping control. As expected, LPS stimulation induced surface expression of MHC 
class II in nearly 50% cells; however, essentially no change in MHC class II expression 
was observed in butyrate-treated HD11 cells (Fig. 8). These results collectively indicated 
that butyrate is incapable of modulating phagocytosis, oxidative burst or activation status 
of macrophage cells. Augmentation of the antibacterial activity in response to butyrate 
treatment, therefore, is likely due to specific induction of endogenous synthesis of HDPs.  
3.4. Oral supplementation of butyrate reduces S. enteritidis colonization in the 
cecum of infected chickens 
Because enhanced HDP gene expression and antibacterial activities were 
observed in cells in response to butyrate treatment, we evaluated whether 
supplementation of feed with butyrate can reduce the survival of pathogenic bacteria in 
the intestinal tract of 5-day-old broilers in two separate trials. Chickens were fed with and 
without 0.1% and/or 2% butyrate for 2 days prior to intraesophageal inoculation of S. 
enteritidis phage type 13a for another 4 days. The cecal contents, where S. enteritidis 
most heavily colonizes, were aseptically harvested and subjected to serial plating on 
Brilliant Green agar plates containing 20 µg/ml of nalidixic acid for specific enumeration 
of S. enteritidis 13a. In trial 1, oral supplementation of 0.2 % butyrate resulted in 1-log 
reduction in the median counts of inoculated bacteria in the cecal content, relative to the 
control group (Fig. 9A). In trial 2, 0.1% butyrate significantly reduced bacterial load (P = 
0.03) in the cecal content of the chickens, whereas 0.2% butyrate led to a less reduction 
of bacterial counts (Fig. 9B). This is perhaps not surprising, given the earlier findings 
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that, as compared to 0.1% butyrate, 0.2% butyrate supplementation caused less induction 
of the HDP genes in the intestinal tract (Fig. 4).  
 
4. DISCUSSION 
 
As a major species of short-chain fatty acids produced from fermentation of 
undigested dietary fiber by intestinal microflora, butyrate exerts a plethora of effects on 
intestinal health and disease [27, 28, 40].  In addition to being a primary energy source 
for colonocytes in mammals, butyrate has been found to play an important role in the 
digestive tract by stimulating mucin synthesis and intestinal motility, cell proliferation 
and differentiation, while suppressing inflammatory diseases [27, 28, 40]. In the present 
study, we have revealed a novel role for butyrate in host defense and extended earlier 
findings that butyrate-induced synthesis of HDPs not only occurs in humans and rabbits 
[29-31], but is also conserved in chickens. We have presented both in vitro and in vivo 
evidence showing that butyrate strongly induces the expressions of multiple HDPs in 
different cell and tissue types including HD11 macrophages, primary monocytes, bone 
marrow cells, jejunum and cecal explants as well as in crop, cecum, and cecal tonsils of 
chickens. The results clearly suggest that transcriptional regulatory mechanisms of many 
HDPs are phylogenetically conserved across mammals and aves.  
It is important to note that only a subset of chicken HDPs are regulated by 
butyrate (Fig. 2), implying that HDPs are differentially regulated even within the same 
family. Consistently, only LL-37 and human β-defensin-2 were reported to be regulated 
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by butyrate in humans [30, 31, 43]. For those chicken HDP genes that are modulated by 
butyrate, we observed a clear cell-specific regulation pattern as evidenced by marked 
differences in the magnitude of induction among different cell types. For example, 
treatment with 4 mM butyrate for 24 h induced the AvBD9 gene approximately 3,000- to 
5,000-fold in HD11 macrophage cells, but only 200-fold in primary monocytes, 700-fold 
in bone marrow cells, 140-fold in jejunal explants, and 5-fold in cecal explants (Figs. 1 
and 3). Several other HDPs, e.g., AvBD14 and cathelicidins B1 were also regulated 
differently among individual cell types (Fig. 3 and data not shown).  
Although we could not detect the synthesis of chicken HDPs at the protein level 
in response to butyrate treatment due to a lack of specific antibodies, we observed an 
increased HDP gene synthesis leading to an enhanced antibacterial activity in monocytes 
in vitro and augmented intestinal bacterial clearance in vivo following butyrate treatment. 
A nearly 10-fold reduction in the bacterial titer was achieved in the cecal contents of the 
chickens fed 0.1% or 0.2% butyrate (Fig. 9). Given the rapid rate of absorption and 
metabolism, the majority of supplemented butyrate is known to be taken up by the upper 
digestive tract, with very small quantities reaching the lower intestinal tract or general 
circulation [39, 40]. A more pronounced reduction in the cecal bacterial titer may be 
achieved if supplemented butyrate can be protected when passing through the upper 
digestive tract or if more butyrate can be produced in the cecum by manipulating the 
conditions of local bacterial fermentation [39, 40].  
It is noteworthy that 0.1% butyrate gave a better bacterial reduction than 0.2% 
butyrate in our feeding trial (Fig. 9B), in agreement with the finding that 0.1% butyrate 
supplementation led to a higher level of the AvBD9 gene transcription in the crop, cecum, 
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and cecal tonsil of chickens than 0.2% butyrate (Fig. 4). Consistently, 8 mM butyrate 
failed to stimulate the synthesis of a higher amount of the AvBD9 transcripts in HD11 
cells than 4 mM butyrate (Fig. 1B). In fact, higher concentrations of butyrate often lead to 
cytotoxicity, growth arrest, and apoptosis [27, 28, 40]. The optimal dose of butyrate for in 
vivo applications, therefore, needs to be investigated carefully for each animal species.  
It was reported earlier that oral supplementation of 0.63 g/kg or 0.92 g/kg of 
butyrate reduces colonization and shedding of S. enteritidis in the cecum of chickens [44, 
45]. However, the mechanism by which butyrate suppresses bacterial growth remain 
elusive, although it was proposed to be a result of the direct antibacterial activity of 
butyrate [46, 47] or a decrease in the invasiveness of Salmonella through intestinal 
epithelial cells following exposure to butyrate [36, 47]. However, because especially high 
concentrations of butyrate (25, 50, and 100 mM) were needed to kill bacteria or 
negatively impact on bacterial invasiveness [36, 46, 47], it is uncertain whether these 
proposed mechanisms may occur in vivo, given that most butyrate is absorbed in the 
upper digestive tract if supplemented orally [39, 40] and that cecal concentrations of 
butyrate are only < 6 mM in 18-day-old  healthy broiler chickens  and < 1 mM in 4-day-
old chickens [47]. More importantly, an increased invasion to intestinal epithelial cells 
was observed in the same study when S. enteritidis was pre-incubated with a mixture of 
short-chain fatty acids mimicking the in vivo cecal concentrations [47]. Here, we 
uncovered a novel mechanism that we believe accounts primarily for butyrate-mediated 
suppression of intestinal bacterial colonization. We found that at physiological 
concentrations butyrate fails to inhibit bacteria directly, but increase the antibacterial 
activity of host innate immune cells by inducing the synthesis of an array of HDPs with a 
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minimum impact on the phagocytic and oxidative killing capacity as well as activation 
status of host cells. Therefore, it is the production of HDPs that is mainly responsible for 
a reduction of bacterial colonization in the intestinal tract of chickens following oral 
supplementation of butyrate. 
Our in vitro and in vivo studies have firmly established that butyrate has a strong 
capacity to induce HDP synthesis and that supplementation of butyrate can augment 
disease resistance and reduce bacterial colonization in chickens. Therefore, the strategies 
for efficient delivery of butyrate to the lower intestinal tract will have important 
implications in animal health and food safety. Indeed, the microencapsulated form of 
butyrate proves to be more efficient in suppressing bacterial growth in the ceca of 
chickens than the free unprotected form [44, 45]. Alternatively, identification and 
application of less labile forms of butyrate analogs in the feed may also prove to be more 
desirable. In fact, several butyrate analogs have been shown to be capable of inducing 
HDP gene expression in humans [48] and such analogs await further testing for their 
antibacterial efficacy in other animal species such as chickens. Besides direct 
administration of butyrate and its analogs, the dietary approaches that promote the 
proliferation of butyrate-producing bacteria and stimulate the fermentation of butyrate 
through the use of prebiotics may also have good prospect to augment HDP synthesis and 
host defense.  
In summary, we have revealed that butyrate-induced synthesis of endogenous 
HDPs is a phylogenetically conserved mechanism of innate host defense shared by both 
mammals and chickens. Moreover, we propose that butyrate-induced HDP synthesis 
represents a newly discovered mechanism that mainly accounts for the suppression of 
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bacterial colonization and shedding in farm animals by butyrate. Coupled with anti-
inflammatory effects and other beneficial properties, butyrate, butyrate analogs, and 
perhaps other short-chain fatty acids may have potential for further development as 
antibiotic-alternative food or feed additives to boost innate immunity and disease 
resistance of humans and animals without provoking a harmful proinflammatory 
response. 
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Table 1. Primer sequences of chicken Avian β-defensins (AvBDs) for real time PCRa 
 
 
            Forward primer Reverse primer 
Product size (bp) 
cDNA Gene 
AvBD1 ATGCGGATCGTGTACCTGCTC CTGCTTGGGATGTCTGGCTCT 219 1197 
AvBD2 CTCTCTCCTCTTCCTGGCAC GAGGGGTCTTCTTGCTGCTG 265 1122 
AvBD3 ATGCGGATCGTGTACCTGCTC CAGAATTCAGGGCATCAACCTC 196 2379 
AvBD4 CATCTCAGTGTCGTTTCTCTGC ACAATGGTTCCCCAAATCCAAC 321 899 
AvBD5 CTGCCAGCAAGAAAGGAACCTG TGAACGTGAAGGGACATCAGAG 300 1100 
AvBD6 AGGATTTCACATCCCAGCCGTG CAGGAGAAGCCAGTGAGTCATC 249 1203 
AvBD7 CTGCTGTCTGTCCTCTTTGTGG CATTTGGTAGATGCAGGAAGGA 230 665 
AvBD8 TTCTCCTCACTGTGCTCCAA AAGGCTCTGGTATGGAGGTG 124 383 
AvBD9 GCAAAGGCTATTCCACAGCAG AGCATTTCAGCTTCCCACCAC 211 1802 
AvBD10 TGGGGCACGCAGTCCACAAC ATCAGCTCCTCAAGGCAGTG 298 2285 
AvBD11 ACTGCATCCGTTCCAAAGTCTG TCGGGCAGCTTCTCTACAAC 301 1299 
AvBD12 CCCAGCAGGACCAAAGCAATG GTGAATCCACAGCCAATGAGAG 335 731 
AvBD13 CATCGTTGTCATTCTCCTCCTC ACTTGCAGCGTGTGGGAGTTG 175 4514 
AvBD14 CTCCTGTTTCTTGTTCTCCTG CACTTTGCCAGTCCATTGTAG 149 501 
a
 Primers for AvBD4-13 are adopted from reference 15. 
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Table 2. Primer sequences of GAPDH, chicken cathelicdin/fowlicidin family and 
cytokines for real time PCRa            
               
 Forward primer Reverse primer 
Product size (bp) 
cDNA Gene 
Cath-B1 CCGTGTCCATAGAGCAGCAG AGTGCTGGTGACGTTCAGATG 170 251 
Fowlicidin-1 GCTGTGGACTCCTACAACCAAC GGAGTCCACGCAGGTGACATC 261 882 
Fowlicidin-2 CAAGGAGAATGGGGTCATCAG CGTGGCCCCATTTATTCATTCA 221 584 
Fowlicidin-3 GCTGTGGACTCCTACAACCAAC TGGCTTTGTAGAGGTTGATGC 352 1095 
IL-1β GACATCTTCGACATCAACCAG CCGCTCATCACACACGACAT 215 384 
IL-8 GCTGATCGTAAAGGCACTTATG GTGAAAGGTGGAAGATGGAATG 159 727 
IL-12p40 GACCCACCTCAATGTCAGTATG GCCCAGTCTTTGGAATCTGAAT 184 1456 
GAPDH GCACGCCATCACTATCTTCC CATCCACCGTCTTCTGTGTG 356 876 
a
 Primers for GAPDH are adopted from reference 15. 
  
Gene 
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Fig. 1. Butyrate-induced expression of the AvBD9 gene in different chicken cell 
types. HD11 macrophage cells were incubated in duplicate with 4 mM sodium butyrate 
for indicated time points (A) or indicated concentrations of butyrate for 24 h (B). 
Chicken primary monocytes (C) or bone marrow cells (D) were exposed to different 
concentrations of butyrate in duplicate for 24 h prior to isolation of total RNA. The 
AvBD9 gene expression was analyzed by real-time RT-PCR, and the relative fold 
increase over the control group was calculated using the comparative ∆∆Ct method and 
the GAPDH gene for normalization. The bars represent means ± standard error of the 
data from 2-3 independent experiments. *P < 0.05, ** P < 0.001, and *** P < 0.0001 
by unpaired Student’s t-test as compared to the untreated control. 
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Fig. 2. Induction of HDP gene expression in chicken HD11 macrophages and primary 
monocytes. Chicken HD11 macrophage cells and primary monocytes were incubated in 
duplicate with and without different concentrations of butyrate for 24 h, followed by RNA 
isolation and real-time RT-PCR analysis of all 14 chicken β-defensins (AvBDs) and 4 
cathelicidins (fowlicidins 1-3 and cathelicidin B1). The color elements represent average log2 
ratios of fold change from 2-3 independent experiments. Red indicates up-regulation, whereas 
black means no induction and green down-regulation. Gray areas are an indication of no data 
due to extremely low expression levels of certain HDPs in primary monocytes. Three groups 
of chicken HDPs, namely generally induced (I), non-regulatable (II), and generally down-
regulated (III), can be classified according to their mode of modulation by butyrate. AvBD11, 
AvBD12, and AvBD13 could not be reliably detected in either cell type, and therefore, were 
not shown. The heat map was generated by using MultiExperiment Viewer [1]. 
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Fig. 3. Up-regulation of three representative HDPs in chicken jejunal (A) and cecal 
explants (B) by butyrate. Chicken jejunum and cecal explants were obtained by 
culturing slices of 0.5 cm long segments, followed by incubation with indicated 
concentrations of butyrate in duplicate for 24 h. Real time RT-PCR was performed and 
the relative fold increase over the control group was calculated using the comparative 
∆∆Ct method and the GAPDH gene for normalization. The bars represent means ± 
standard error of the data from two independent experiments. *P < 0.05, ** P < 0.001, 
and *** P < 0.0001 by unpaired Student’s t-test as compared to the untreated control. 
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Fig. 4.  In vivo induction of the AvBD9 gene expression in the intestinal tract of 
chickens by butyrate.  Two-day-old male Cornish Rock broilers were fed with standard 
ration with or without supplementation of 0.1% and 0.2% butyrate for 2 days. The crop, 
cecal tonsil, and cecum were collected from each chicken and the AvBD9 gene 
expression was evaluated by real-time PCR. Each bar represents means ± standard error 
of the data from 6 different chickens. * P < 0.05 by unpaired Student’s t-test. 
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Fig. 5. Minimum triggering of proinflammatory cytokine synthesis in HD11 cells by 
butyrate. Chicken HD11 macrophage cells were incubated with indicated concentrations 
of butyrate or 1 µg/ml LPS in duplicate for 3 and 24 h, followed by real-time PCR 
analysis of the gene expressions of  IL-1β (A), IL-12p40 (B), and IL-8 (C). The bars 
represent means ± standard error of the data from two independent experiments. 
Essentially no induction of IL-1 and IL-12p40 was observed at both 3 and 24 h after 
butyrate stimulation, with moderate induction of IL-8 occurring only following butyrate 
treatment for 24 h. 
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Fig. 6. Augmentation of the antibacterial activity of monocytes following stimulation 
with butyrate. Chicken monocytes were treated with or without different concentrations 
of butyrate for 24 h. Cell lysates were then prepared and incubated with S. enteritidis 
(ATCC 13076) for 9 h at 37oC. Bacterial turbidity at OD590nm was measured as an 
indication of the bacterial density. S. enteritidis was also directly incubated with different 
concentrations of butyrate in cell culture medium alone without monocytes as controls 
(white bars). The bars represent means ± standard error of the data from two independent 
experiments. ** P < 0.001, and *** P < 0.0001 by unpaired Student’s t-test as compared 
to the untreated control. 
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Fig. 7. No impact of butyrate on phagocytic (A) or oxidative burst activities (B) of 
HD11 cells. For both assays, chicken HD11 macrophage cells were incubated with 
different concentrations of butyrate in duplicate for 24 h, followed by exposure to S. 
enteritidis phage type 13a for 30 min at 37oC in the presence of 5% chicken serum for 
phagocytosis assay. Extracellular bacteria were then killed by gentamicin, and 
internalized bacteria were enumerated from lyzed HD11 cells by serial plating on 
Brilliant Green agar plates containing 20 µg/ml nalidixic acid overnight at 37oC.  In the 
oxidative burst assay, the fluorescence was monitored following 1 h incubation with 
DCFA in the presence or absence of phorbol 12-myristate 13-acetate (PMA). The results 
were normalized against protein concentrations of each sample. The bars represent means 
± standard error of the data from two independent experiments.  
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Fig. 8. No influence on the activation status of HD11 cells by butyrate. HD11 cells 
were incubated with 4 mM butyrate, 1 µg/ml LPS or left untreated for 24 h, followed by 
flow cytometric analysis of surface expression of MHC class I and II using fluorescein 
isothiocyanate (FITC)-conjugated anti-chicken MHC class I and R-phycoerythrin (R-
PE)-conjugated anti-chicken MHC class II monoclonal antibodies.  The data shown are 
representative of two independent experiments. 
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Fig. 9. Reduction of the S. enteritidis titer in the cecal contents of chickens following 
oral supplementation of butyrate. In trial 1 (A), 5-day old male broilers were equally 
divided into two groups of 10 and fed with a standard antibiotic-free diet mixed with and 
without 0.2% sodium butyrate for 2 days. Birds were then inoculated with 1 × 106 CFU 
of S. enteritidis phage type 13a and continued with butyrate feeding for another 4 days. 
The S. enteritidis titer in the cecal content was quantitated from each animal by serial 
plating on Brilliant Green agar plates containing 20 µg/ml nalidixic acid. Trial 2 (B) was 
similarly conducted with an additional group of 10 broilers fed with 0.1% butyrate. Each 
dot represents the bacterial titer from a bird and the solid line represents the median value 
of each treatment.  Brackets indicate the statistical significance of differences (*P = 0.03, 
unpaired Student’s t-test). 
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ABSTRACT 
 
Widespread use of antibiotics as growth promoters in food animal production has 
been criticized to be a major driving force for emergence of antimicrobial resistant 
pathogens, which has become a serious public health concern worldwide. Development 
of antibiotic-alternative approaches to disease control and prevention is imperatively 
needed. Previously, we showed that butyrate, a major species of short-chain fatty acids 
(SCFAs) fermented from undigested fiber by intestinal microflora, is a potent inducer of 
endogenous antimicrobial host defense peptide (HDP) genes in the chicken. In the 
present study, we further revealed that, in chicken HD11 macrophage cells and primary 
monocytes, expression of HDPs is largely in an inverse correlation with the aliphatic 
carbon chain length of free fatty acids, with SCFAs being the most potent, medium-chain 
fatty acids moderate and long-chain fatty acids essentially ineffective. Additionally, three 
SCFAs, namely acetate, propionate, and butyrate, exerted a strong synergy in augmenting 
HDP synthesis in chicken cells. Consistently, supplementation of chickens with a 
combination of the three SCFAs in water resulted in a further reduction of S. enteritidis in 
the cecum as compared to feeding of individual SCFAs. More importantly, free fatty 
acids enhanced HDP gene expression without triggering proinflammatory interleukin-1β 
production. Taken together, oral supplementation of SCFAs is capable of boosting host 
immunity and disease resistance, with potential in disease control and prevention in 
animal agriculture without relying on antibiotics. 
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1. INTRODUCTION 
 
Use of antibiotics as growth promoters is suspected to be a major source for the 
development of antibiotic-resistant pathogens, which have become a major public health 
concern worldwide. Enhancing host immunity and disease resistance by specifically 
boosting the synthesis of endogenous host defense peptides (HDPs) may represent a 
promising antibiotic-alternative strategy. HDPs have been found in nearly all forms of 
life and play an important role in the first line of defense [1-3]. HDPs kill a broad range 
of microbes including bacteria, fungi, parasites, and enveloped viruses mainly through 
physical interaction and disruption of the membranes [1-3]. It is, therefore, extremely 
difficult for pathogens to develop resistance [1-3]. In addition to their direct antimicrobial 
activities, HDPs play a profound role in potentiating the immune response to infections 
by recruiting and activating immune cells, binding and neutralizing bacterial endotoxins, 
and promoting wound healing [1-4]. Because of these pleiotropic effects, it is beneficial 
to specifically enhance the synthesis of endogenous HDPs for disease control and 
prevention.                                                                                       
As an important source of energy, fatty acids are represented by a large group of 
carboxylic acids with an aliphatic hydrocarbon chain that are either saturated or 
unsaturated. Based on the number of carbon atoms in the aliphatic chain, fatty acids are 
broadly classified into three groups, namely SCFAs (≤ C5), medium-chain fatty acids 
(MCFAs) (C6 to C11), and long-chain fatty acids (LCFAs) (≥ C12) [5]. Butyrate, acetate 
and propionate are the major species of SCFAs produced by bacterial fermentation of 
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resistant starch, cellulose, and sugar in the intestine [6-8]. The concentrations of acetate, 
propionate, butyrate vary in molar ratios from 48:29:23 to 70:15:15 in human feces [7] 
and 33:12:6 in chicken cecal contents [9]. Besides being a major source of energy and 
constituents of cellular membranes, fatty acids also play an important role in maintaining 
homeostasis of intestinal physiology by regulating fluid absorption, gut motility, gut 
microbiota, and mucosal inflammation as well as proliferation, differentiation, and 
apoptosis of intestinal epithelial cells [10-15].  
Earlier studies reported that SCFAs including butyrate and propionate are capable 
of inducing the synthesis of LL-37, a HDP in humans [12], which is largely due to their 
histone deacetylase inhibitory activity [14].  Inhibition of histone deacetylase is known to 
promote hyper-acetylation of the lysine residues in nucleosome core histones leading to a 
less compact chromatin and transcriptional activation of a subset of genes [16, 17]. 
Indeed, several other histone deacetylase inhibitors were also found to be capable of 
inducing HDP gene expression in humans, albeit with a varying potency [14, 18].  
We recently reported that butyrate enhances HDP expression in several different 
cell types including macrophages, monocytes, and intestinal epithelial cells [19]. In the 
present study, we further compared the relative potency in HDP induction by free fatty 
acids of various aliphatic chain lengths (C1 to C18). There was an inverse correlation 
between the expression of HDPs and the length of aliphatic chain of fatty acids, with 
SCFAs being the strongest inducers. Saturation or unsaturation of the aliphatic tails of 
fatty acids appeared to play a minimum role of HDP induction. We further revealed a 
strong synergy among three SCFAs including acetate, propionate, and butyrate in 
enhancing AvBD9 expression and reducing bacterial colonization in the chicken, 
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suggesting the potential for dietary supplementation of SCFAs in disease control and 
prevention. 
 
2. MATERIALS AND METHODS 
 
2.1. Chemicals 
Formate, acetate, propionate, butyrate, hexanoate, n-octanoate, decanoate, linoleic acid 
(ω-6), α-linolenic acid (ω-3), conjugated linoleic acid (CLA), and trichostatin A (TSA) 
were purchased from Sigma-Aldrich (St. Louis, MO), whereas heptanoate, nonanoate, 
dodecanoate, tetradecanoate, octadecanoate were from TCI America (Portland, OR). All 
free fatty acids were purchased in the sodium salt form, except for linoleic acid, linolenic 
acid, and CLA, which were in the free acid form. SCFAs (formate, acetate, propionate, 
and butyrate), MCFAs (hexanoate, heptanoate, n-octanoate, nonanoate, and decanoate) 
were dissolved in RPMI 1640 cell culture medium, while LCFAs (dodecanoate, 
tetradecanoate, and octadecanoate) were dissolved in methanol and free linoleic acid, 
linolenic acid and CLA were dissolved in ethanol. Bacterial lipopolysaccharide (LPS) 
from E. coli O111:B4 was purchased from Sigma-Aldrich and dissolved in RPMI 160 
medium.  
2.2. Isolation, culture, and stimulation of chicken cells  
Chicken HD11 macrophage cells (kindly provided by Dr. Hyun S. Lillehoj from USDA, 
ARS) were cultured in 6-well plates in RPMI 1640 containing 10% FBS and 1% 
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streptomycin/ penicillin at 2 x 106 cells/well. After overnight growth, HD11 cells were 
incubated with various fatty acids. Chicken peripheral blood mononuclear cells (PBMCs) 
were isolated from EDTA-anticoagulated venous blood by gradient centrifugation using 
Histopaque 1077 (Sigma). Cells in the interphase were then collected, washed in Hank’s 
balanced salt solution (HBSS), and then resuspended in RPMI 1640 containing 10% FBS, 
1% streptomycin/pencillin, and 20 mM HEPES in 60-mm tissue culture dishes at 6 x 107 
cells/dish. After overnight incubation at 37oC and 5% CO2, non-adherent cells were 
washed off with HBSS, and adherent monocytes were used subsequently for stimulation 
with fatty acids. Each treatment was performed in duplicate or triplicate and repeated at 
least 2-3 times. For all experiments, equal amounts of solvents were added to cells as 
negative controls. All chemicals were tested for their toxicity to chicken cells, and the 
subtoxic concentration ranges that gave the maximal induction of HDP expression were 
presented. 
2.3. Analysis of chicken gene expression by real time RT-PCR 
Following stimulation, cells were harvested with RNAzol (Molecular Research), and total 
RNA was extracted according to the manufacturer’s instructions. The first-strand cDNA 
was synthesized from 300 ng of total RNA with QuantiTect Reverse Transcription Kit 
(Qiagen), and real time PCR was performed with QuantiTect SYBR Green PCR Kit 
(Qiagen) using 1/40 (for GAPDH) or 1/10 (for HDP genes) of the first-strand cDNA and 
gene-specific primers in a total volume of 10 µl as previously described [20-22]. The 
PCR was set for initial denaturation at 95oC for 10 min, followed by 45 cycles of 94oC 
for 15 sec, 55oC for 20 sec, and 72oC for 30 sec.  A melt curve analysis step was also 
included to ensure the specificity of PCR amplification. Chicken glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) was used as a house keeping gene for data 
normalization. The forward and reverse primers for chicken GAPDH, HDPs (AvBD9 and 
cathelicidin B1), and proinflammatory cytokines (IL-1β, IL-8, and IL-12p40) were 
previously described [20]. Relative changes in the gene expression level were quantified 
with the ∆∆Ct method as described [20-22].  
2.4. Histone deacetylase (HDAC) assay  
HDAC assay was performed using the Fluor-de-Lys® HDAC Fluorimetric Cellular 
Activity Assay Kit (Enzo Life Sciences, PA) according to the manufacturer’s 
instructions. Chicken HD11 cells (1 × 105) were cultured in phenol red-free RPMI 1640 
containing 10% FBS in a 96-well tissue culture plate overnight. Cells were treated in 
duplicate with or without SCFAs in the presence of 100 µM of Fluor-de-Lys®, a 
fluorogenic, cell-permeable HDAC substrate for 4 h. The deacetylation reaction was then 
stopped by addition of TSA, a strong HDAC inhibitor, in a cell lysis buffer containing 
1% NP-40, The fluorescent signal was generated by addition of a developer solution to a 
final concentration of 1 µM, and the fluorescence was recorded at 360 nm excitation and 
460 nm emission using FLx800 Multi-Detection Microplate Reader (Bio-Tek 
Instruments). The HDAC inhibitory activity (%) was calculated as [1 – (Ftreatment –  
Fbackground)/(Fmax – Fbackground)]  × 100, where Ftreatment is the fluorescence of cells exposed 
to SCFAs, Fmax is the maximum fluorescence of cells without being exposed to SCFAs, 
and Fbackground is the fluorescence of cell culture medium without cells.  
2.5. Oral supplementation of SCFAs and experimental infection of chickens with 
Salmonella enteritidis   
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A total of 20, day-of-hatch male Cornish Rock broiler chickens were purchased from a 
commercial hatchery (Ideal Poultry, Cameron, TX) and were equally divided into four 
groups with 5 birds/group and fed with a standard antibiotic-free ration and deionized 
water ad libitum for 4 days. Water containing 0.5% sodium acetate, 0.2% propionate 
and/or 0.1% butyrate was provided ad libitum for each group for 2 days, prior to an 
intraesophageal infection with 0.5 ml of Lysogeny broth ( LB) containing 1 × 107 CFU of 
S. enteritidis phage type 13a (a kind gift from Dr. Susan Lamont at Iowa State 
University) [23]. After administration of SCFAs in water for another 4 days, the birds 
were euthanized and cecal contents were aseptically collected from each animal, serially 
diluted in PBS, and plated on Brilliant Green agar plates (Becton Dickinson) containing 
20 µg/ml of nalidixic acid for overnight growth and bacterial enumeration. All animal 
procedures were approved by the Institutional Animal Care and Use Committee of 
Oklahoma State University.  
2.6. Statistical analysis 
Unpaired Student’s two-tailed t-test was used to evaluate the statistical significance using 
GraphPad Prism 5 (GraphPad Software, La Jolla, CA).  P < 0.05 was considered 
statistically significant.  
 
3. RESULTS AND DISCUSSION 
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3.1. Inverse correlation between the HDP-modulating ability and aliphatic chain 
length of free fatty acids  
To examine the effect of free fatty acids of various aliphatic carbon chain lengths 
on the expression of a representative chicken β-defensin (AvBD9), we incubated chicken 
macrophage HD11 cells and primary monocytes with different concentrations of fatty 
acids for 24 h and then examined AvBD9 gene expression by real-time RT-PCR. As 
shown in Fig. 1A, we observed a clear dose-dependent induction of AvBD9 in HD11 
cells in response to SCFAs and MCFAs, with LCFAs being largely inactive. A peak 
response occurred with SCFAs, with greater than 1000-fold induction of AvBD9 gene 
expression in HD11 cells when exposed to 80, 64, and 4 mM of acetate, propionate, and 
butyrate, respectively. The magnitude of AvBD9 induction was dramatically reduced 
with MCFAs (Fig. 1A) when compare to SCFAs. A similar trend was also observed in 
primary chicken monocytes, with SCFAs being the most potent inducers (Fig. 1B). 
However, a notable difference is that LCFAs including dodecanoate (C12), 
tetradecanoate (C14), and octadecanoate (C18) maintained a comparable, if not slightly 
better, AvBD9-inducing activity than MCFAs in primary monocytes (Fig. 1B). 
Besides AvBD9, we also examined another representative chicken HDP, namely 
cathelicidin B1, in response to free fatty acids in chicken primary monocytes. Similar to 
AvBD9, cathelicidin B1 was most readily induced by SCFAs including acetate, 
propionate, and butyrate (Fig. 2). The maximum induction of cathelicidin B1 expression 
was 17-fold for acetate, 37-fold for propionate, and 29-fold for butyrate, respectively. 
However, MCFAs and LCFAs had little or no impact on cathelicidin B1 synthesis.  
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To further examine the effect of the saturation status of the aliphatic chain on 
HDP expression, different concentrations of oleate [C18:(n-9)], linoleic acid [C18:2(n-
6)], α-linolenic acid [C18:3(n-3)], and CLA were used to stimulate HD11 cells for 24 h. 
Real-time RT-PCR revealed that, in contrast to saturated LCFAs,  unsaturated long chain 
fatty acids including oleate, linoleic acid, α-linolenic acid, and CLA were incapable of 
inducing AvBD9 gene expression in HD11 cells (Fig. 3A), but clearly showed a 
statistically significant, dose-dependent induction of the AvBD9 expression in primary 
chicken monocytes (Fig. 3B), showing a seemingly more potent HDP-modulating activity 
than saturated, unbranched LCFAs. Over all, these findings surprisingly suggested the 
significance of double bonds in the regulation of HDP expression. It appears that 
presence of double bonds in LCFAs tends to increase their ability to modulate AvBD9 
gene expression, with an opposite effect seen with saturated LCFAs. However, additional 
unsaturated fatty acids need to be tested in order to strengthen the conclusion, and the 
underlying mechanisms warrant further investigations. 
3.2. Impact of free fatty acids on the inflammatory response in HD11 cells  
SCFAs, particularly Butyrate, generally exert anti-inflammatory effects and have 
been used to treat inflammatory bowel diseases [7, 8]. To confirm augmentation of HDP 
gene expression by free fatty acids without triggering a proinflammatory response, we 
treated HD11 cells with or without different fatty acids at optimal HDP-inducing 
concentrations for 3 and 24 h and analyzed the expressions of three representative 
cytokines including IL-1β, IL-8, and IL-12p40. Bacterial lipopolysaccharide (LPS) from 
E. coli O111:B4 at 1 µg/ml was used as a positive control. All representative fatty acids, 
including acetate, propionate, butyrate, hexanoate, and octanoate, had essentially no 
  
86 
effect on IL-1β at both time points (Fig. 4). No influence on IL-12p40 expression was 
observed following fatty acid stimulation for 3 h; however, a 3- to 10-fold induction was 
seen with all fatty acids except for butyrate. As compared with LPS that caused >1000-
fold induction, a minimum influence (~10-fold increase) on IL-8 expression was 
observed after 3 h stimulation; however, all fatty acids showed a IL-8-inducing activity 
comparable to LPS after 24 h (Fig. 4). Taken together, these results demonstrated that 
fatty acids generally have no or a mild influence on triggering the inflammatory response 
while promoting the production of HDPs.  
3.3. Synergistic induction of AvBD9 expression and reduction of bacterial 
colonization by SCFAs  
Because acetate, propionate, and butyrate are among the most potent fatty acids in 
inducing AvBD9 gene expression and they also represent the major species of SCFAs 
being produced simultaneously by intestinal microflora, we sought to determine the 
synergistic effect of these three SCFAs on HDP synthesis. Chicken HD11 cells and 
primary monocytes were treated with acetate, propionate, and butyrate individually or in 
combinations for 24 h and followed by real-time RT-PCR analysis of AvBD9 gene 
expression. Individual SCFAs at low concentrations gave a minimum induction of 
AvBD9 gene in both HD11 cells and primary monocytes (Figs. 5A and 5B). However, a 
combination of propionate and acetate showed an obvious synergism (Fig. 5). More 
strikingly, an addition of all three SCFAs resulted in a significant induction of the 
AvBD9 gene in both cell types when compared to individual fatty acids (Fig. 5). A 
combination of all three free fatty acids enhanced AvBD9 gene expression with a 
maximum increase of 4,000-fold in HD11 cells and 25- to 50-fold in primary monocytes. 
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SCFAs and butyrate in particular are well-known histone deacetylase inhibitors 
[16, 17]. To study the impact of histone deacetylation on the AvBD9-inducing activity in 
chickens by SCFAs, we treated HD11 cells with or without acetate, propionate, and 
butyrate individually or in combination for 4 h and then performed HDAC assays using 
Fluor-de-Lys® HDAC Fluorimetric Cellular Activity Assay Kit (Enzo Life Sciences). As 
shown in Fig. 6, low concentrations of butyrate (0.5 mM) and acetate (40 mM) showed a 
similar HDAC inhibitory activity of approximately 50%, while propionate (4mM) 
suppressed the HDAC activity by 67% (Fig. 6). Moreover, a combination of any two 
SCFAs showed comparable or higher HDAC inhibitory activity than any individual 
SCFAs. More importantly, simultaneous treatment of HD11 cells with all three SCFAs 
resulted in the greatest inhibition of the HDAC activity (83%) (Fig. 6). These results are 
precisely correlated with the relative capacity of SCFAs to stimulate AvBD9 gene 
expression, where individual SCFAs gave marginal induction, combination of two caused 
a marked increase in AvBD9 expression, and the most dramatic augmentation occurred 
with three SCFAs (Fig. 5). Our data are also consistent with earlier findings that SCFAs 
induced HDP synthesis mainly through inhibition of HDACs in humans [14]. 
To further confirm whether SCFA-mediated synergistic induction of HDP could 
confer animals an enhanced resistance to bacterial infection, we supplemented 4-day-old 
male broiler chickens with 0.5% acetate, 0.2% propionate, and 0.1% butyrate individually 
or in combination in water for 2 days, followed by an inoculation with 1 x 107 CFU of S. 
enteritidis for another 4 days. The bacterial titer in the cecal content was examined. As 
seen in Fig. 7, a significant reduction of the S. enteritidis load was observed with 
supplementation of acetate, propionate, and butyrate individually. Importantly, the most 
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dramatic reduction in bacterial colonization was seen in the chickens receiving a 
combination of three SCFAs, consistent with their ability to induce AvBD9 gene 
expression in vitro (Fig. 5). It is likely that newly synthesized HDPs are released into 
extracellular compartments, killing microbes on mucosal surfaces [24].  
In the present study, we have shown among all free fatty acids, SCFAs are the 
most potent inducers of HDP gene expression in the chicken without provoking excessive 
proinflammatory response. Furthermore, the HDP-inducing activity of SCFAs is strongly 
correlated with their ability to inhibit the HDAC activity. It is worth noting that, in 
addition to the capacity to promote HDP synthesis, SCFAs and MCFAs were also found 
to possess direct antibacterial activities, albeit at high concentrations [9, 25]. 
Additionally, MCFAs and SCFAs, except for acetic acid, reduce the ability of Salmonella 
to invade intestinal epithelial cells [9, 25]. Given such a plethora of antibacterial 
properties, free fatty acids, particularly SCFAs, have potential for disease control and 
prevention and may represent promising alternatives to antibiotics.  
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FIGURE AND FIGURE LEGENDS 
 
Fig. 1. Regulation of AvBD9 gene expression by free fatty acids. Chicken macrophage 
HD11 cells (A) and primary monocytes (B) were treated in duplicate with or without 
indicated concentrations of fatty acids (mM) for 24h, followed by real-time RT-PCR 
analysis of AvBD9 gene expression. Data was normalized with GAPDH, and relative 
fold change of each treatment versus solvent control was calculated using ∆∆Ct method. 
Each bar indicates mean ± standard error of the data from 2-3 experiments.  
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Fig. 2. Modulation of cathelicidin B1 gene expression by free fatty acids. Primary 
chicken monocytes were treated in duplicate with or without indicated concentrations of 
free fatty acids (mM) for 24h, followed by real-time RT-PCR analysis of cathelicidin B1 
gene expression. Data was normalized with GAPDH, and relative fold change of each 
treatment versus solvent control was calculated using ∆∆Ct method. Each bar indicates 
mean ± standard error of the data from 2-3 experiments. 
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Fig. 3. Differential expression of AvBD9 in response to unsaturated fatty acids. 
Chicken HD11 macrophage cells (A) and primary monocytes (B) were treated in 
duplicate with different concentrations of sodium oleate (0.1 and 0.2 mM) and linoleic, α-
linolenic, and conjugated linolenic acids (0.05, 0.1, 0.2, and 0.4 mM for all three) for 24 
h, followed by real-time RT-PCR analysis of AvBD9 gene expression. Each bar indicates 
mean ± standard error of the data from two independent experiments. *P < 0.05, ** P < 
0.001, and *** P < 0.0001 by unpaired Student’s t-test as compared to the untreated 
control. 
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 Fig. 4. A minimum impact of free fatty acids on the expression of proinflammatory 
cytokines. Chicken HD11 cells were stimulated with different fatty acids at optimal 
HDP-inducing concentrations (80 mM acetate, 32 mM propionate, 4 mM butyrate, 16 
mM hexanoate, and 2 mM octanoate) or LPS (1 µg/µl) as a positive control for 3 and 24 
h, followed by real-time RT-PCR analysis of the expression of IL-1β (A), IL-12p40 (B), 
and IL-8 (C). The bars represent means ± standard errors from 2-3 experiments. 
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Fig. 5. Synergistic induction of AvBD9 with acetate, propionate and butyrate in 
chicken HD11 cells (A) and primary monocytes (B). Cells were incubated with acetate, 
propionate and butyrate alone or in combinations for 24h, followed by real-time RT-PCR 
analysis of AvBD9 expression. Each bar represents mean ± standard error of the data 
from 3 independent experiments.  *P < 0.05, ** P < 0.001, and *** P < 0.0001 by 
unpaired Student’s t-test as compared to the cells treated with butyrate alone. 
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Fig. 6. Inhibition of the HDAC activity by acetate, propionate, and butyrate. 
Chicken HD11 cells were incubated in duplicate with or without three SCFAs in the 
presence of Fluor-de-Lys®, a fluorogenic, cell-permeable HDAC substrate for 4 h. The 
deacetylation reaction was stopped and the fluorescent signal was generated by addition 
of a developer solution containing trichostatin A and NP-40. Fluorescence was monitored 
at 360 nm excitation and 460 nm emission. HDAC inhibition by SCFAs was calculated 
relative to the cells without being exposed to any HDAC inhibitor. Each bar represents 
mean ± standard error of the data. *P < 0.05, ** P < 0.001, and *** P < 0.0001 by 
unpaired Student’s t-test as compared to the cells treated with butyrate alone. 
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Fig. 7. Synergistic reduction of the S. enteritidis load in the cecum of chickens by a 
combination of acetate, propionate and butyrate. Four day-old male broiler chicks 
were supplemented with or without 0.5% acetate, 0.2% propionate, and 0.1% butyrate 
alone or in combinations in water for 2 days with 5 birds per group, followed by an 
inoculation with S. enteritidis phage type 13a (1 x 107).  SCFA supplementation was 
continued for another 4 days before the cecal content was collected and bacterial number 
enumerated. Each dot indicates the bacterial titer in a bird and the solid line represents the 
median value of each treatment. *P < 0.05 and **P < 0.01 (by unpaired Student’s t-test).  
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ABSTRACT 
As an important component of innate immunity, host defense peptides (HDPs) protect the 
host from invading pathogens by acting as direct antimicrobials and immunomodulators. 
Butyrate, a histone deacetylase (HDAC) inhibitor, was shown to induce the HDP 
expression and reduce the Salmonella enteritidis colonization in chickens. However, the 
molecular mechanism by which butyrate induces chicken HDP expression remains 
elusive. Here we studied the involvement of histone acetylation and cAMP and MAP 
kinase signaling pathways in butyrate-mediated regulation of AvBD9, a chicken β-
defensin in chicken HD11 macrophage cells. We showed that, similar to butyrate, most 
HDAC inhibitors are capable of inducing AvBD9 gene expression, although varying in 
the efficacy. On the other hand, histone acetyltransferase (HAT) inhibitors reversed 
butyrate-induced AvBD9 gene expression. Inhibition of p38 MAP kinase or c-Jun N-
terminal kinase (JNK), but not extracellular signal-regulated kinase (ERK) pathway, 
obliterated butyrate-triggered AvBD9 synthesis. In addition, cAMP analogs and 
adenylate cyclase agonists upregulated AvBD9 gene expression. More importantly, 
butyrate and adenylate cyclase agonists acted synergistically in enhancing AvBD9 gene 
expression. Taken together, our studies revealed a critical involvement of histone 
acetylation, cAMP signaling, and p38 and JNK pathways in the regulation of AvBD9 
gene transcription mediated by butyrate. A detailed understanding of the underlying 
mechanisms of the HDP gene regulation will pave the way for development of novel 
antibiotic-free strategies in diseases control and prevention in both animal agriculture and 
public health.  
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1. INTRODUCTION 
 
Host defense peptides (HDPs) are a critical, evolutionarily conserved component 
of the innate immune system. HDPs are represented by a large group of small cationic 
peptides with generally less than 100 amino acid residues [1-4]. HDPs are expressed 
strategically in leukocytes, skin keratinocytes, and mucosal epithelial cells lining the 
digestive, respiratory, and urogenital tracts, providing an important first line of host 
defense. They are either constitutively expressed or differentially regulated in response to 
infection or injury. HDPs kill bacteria, enveloped virus, protozoa, and fungi mainly by 
physically disrupting their membranes [2, 5-8]. In addition to their direct bacterial killing 
activity, HDPs also modulate innate and adaptive immunity [2, 9]. Two major families of 
HDPs, namely cathelicidins and defensins, exist in vertebrates [4, 10, 11]. Most defensins 
are composed of six conserved cysteine residues in the C-terminal region [10-13], 
whereas cathelicidins consists of a conserved cathelin domain in the N-terminal region 
and a highly variable C-terminal sequence [4, 14]. The chicken genome encodes a total of 
14 avian β-defensins also known as AvBDs and 4 cathelicidins known as fowlicidins 1-3 
[15-17] and cathelicidin B1 [18]. 
Butyrate and a group of histone deacetylase (HDAC) inhibitors were recently 
found to specifically augment LL-37 cathelicidin gene expression in human HT29 
colonic epithelial cells [19-21]. As an important epigenetic mechanism for remodeling of 
the chromatin structure and controlling of gene expression, histone acetylation is 
achieved by a balanced act of histone acetyltransferases (HATs) and HDACs. HATs 
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acetylate the lysine residues of nucleosomal core histones leading to a relaxed and 
transcriptionally active chromatin. Conversely, HDACs remove the acetyl groups from 
the lysine residues resulting in a condensed and transcriptionally silenced chromatin. 
HDAC inhibitors block the action of HDACs, leading to hyper-acetylation of histones, 
thereby affecting gene expression [22-25]. It will be important to reveal the significance 
of histone acetylation in regulating HDP expression in a non-mammalian species. Besides 
epigenetic control, binding of cAMP-response element-binding protein (CREB) and 
activator protein 1 (AP-1) to the promoter region were shown to play a major role in 
butyrate-mediated induction of human LL-37 expression in intestinal epithelial cells [26]. 
Consistently, blockage of cAMP and MAP (mitogen-activated protein) kinase signaling 
essentially abrogated the transcriptional activation of the LL-37 gene by butyrate [26]. 
We found previously that butyrate upregulates the expression of several HDPs 
and reduces the Salmonella enteritidis colonization in the chicken [27]. In the present 
study, we extended our work to have further revealed a critical role of histone acetylation 
and cAMP and MAPK signaling pathways in butyrate-mediated regulation of AvBD9, a 
chicken β-defensin. We also discovered a synergistic induction of AvBD9 gene 
expression by a combination of butyrate and adenylate cyclase agonists. These results 
will have important implications in devising novel immune boosting strategies in disease 
control and prevention without the use of antibiotics. 
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2. MATERIALS AND METHODS 
 
2.1. Chemicals and cells 
Sodium valproate, Sodium butyrate, pertussis toxin (PT) and cholera toxin (CT) were 
purchased from Sigma-Aldrich (St. Louis, MO). Forskolin (FSK), 8-Bromo-cAMP, 
dibutyryl-cAMP (DB-cAMP), SB203580 (p38 inhibitor), PD98059 (MEK inhibitor), and 
SP600125 (JNK inhibitor) were from Santa Cruz Biotechnology (Santa Cruz, CA). 
HDAC inhibitors including trichostatin A (TSA), suberoylanilide hydroxamic acid 
(SAHA), CAY10433/BML-210, and CAY10398 were obtained from Cayman Chemicals 
(Ann Arbor, MI). Epigallocatechin gallate (EGCG), garcinol, and anacardic acid (HAT 
inhibitors) were acquired from Cayman Chemicals (Ann Arbor, MI), Enzo Life Sciences 
(Farmingdale, NY), and Santa Cruz, respectively. Sodium valproate, sodium butyrate, 8-
Bromo-cAMP, DB-cAMP, and PD98059 were dissolved in RPMI 1640 medium. TSA, 
SAHA, CAY10433, and CAY10398, FSK, SB203580, and SP600125 were dissolved in 
dimethyl sulfoxide (DMSO), whereas CT and PT were dissolved in sterile water. Chicken 
HD11 macrophage cell line [28] was a generous gift from Dr. Hyun S. Lillehoj at the 
USDA, ARS. 
2.2. Isolation of chicken primary monocytes 
Chicken blood was collected intravenously using EDTA as anticoagulant (Sigma), and 
peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation 
with Histopaque 1077 (Sigma). Chicken blood was mixed 1:1 with 1% methyl cellulose 
(Sigma), and centrifuged at 25 × g for 20 min. Cells remaining in suspension were
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collected, mix 1:1 with prewarmed Hanks balanced salt solution (HBSS), and centrifuged 
for 15 min at 600 × g. Cells were resuspended with warm HBSS and overlaid onto 
Histopaque 1077 for centrifugation for 30 min at 400 × g. Interphase containing PBMC 
was collected into a fresh tube and washed with HBSS. Cell pellet was then resuspended 
in RPMI 1640 (Hyclone) supplemented with 10% fetal bovine serum (FBS), 100 µg/ml 
streptomycin, 100 U/ml penicillin, and 20 mM HEPES.  PBMCs (6 ×107/well) were 
dispensed in 60 mm tissue culture dishes and let adhere overnight at 37oC and 5% CO2. 
Non-adherent cells were then removed, and adherent monocytes were washed once with 
prewarmed HBSS. Monocytes were replenished with fresh complete RPMI 1640 medium 
and incubated for another 2 h prior to be exposed to different agents. 
2.3. Culture and stimulation of cells 
Chicken HD11 macrophages (2 ×106/well) were grown in 2 ml RPMI 1640 supplemented 
with 10% FBS and 1% antibiotics in 6-well tissue culture plates. After overnight 
incubation at 37oC and 5% CO2, cells were treated with different agents. To study the 
signaling mechanisms in butyrate-mediated HDP induction, cells were incubated with 
cAMP agonists, MAPK kinase inhibitors for 1h and with HAT inhibitors for 2 h, 
followed by butyrate treatment for up to another 24 h. All experiments were performed 2-
3 times independently, with 2-3 biological replicates for each treatment. 
2.4. Total RNA extraction and cDNA synthesis 
Following treatment with different agents, cells were harvested with RNAzol (Molecular 
Research) for isolation of total RNA. The quantity and quality of RNA were measured by 
Nanodrop (NanoDrop Products, Wilmington, DE), and QuantiTect Reverse Transcription 
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Kit (Qiagen, Valencia, CA) was used to synthesize the first-strand cDNA from total RNA 
following the manufacturer’s recommendations. Briefly, 0.3 µg of total RNA was first 
eliminated of genomic DNA contamination in a genomic DNA wipeout buffer for 5 min 
at 42oC. Reverse transcription was then performed in a total volume of 4 µl using 
Quantiscript reverse transcriptase and a mixture of random hexamers and oligo(dT) 
primers for 30 min at 42oC, followed by 3 min at 95oC to inactivate reverse transcriptase. 
The cDNA was then diluted 10-fold with RNase-free water prior to use in real-time PCR. 
2.5. Real-time PCR analysis of gene expression 
QuantiTect SYBR Green PCR Kit (Qiagen) was used for real-time amplification of the 
first-strand cDNA using MyiQ Real Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA) as previously described [17]. Briefly, each PCR reaction was set up in a 96-
well PCR plate in a total volume of 10 µl using 0.1 µg of the first-strand cDNA and gene-
specific primers (Table 1). Real-time PCR was programmed as follows: initial 
denaturation at 95oC for 10 min, followed by 45 cycles of denaturation at 94oC for 15 s, 
annealing at 55oC for 20 s, and extension and data collection at 72oC for 30 s. The 
forward and reverse primers for chicken GAPDH and AvBD9 and proinflammatory 
cytokines were previously described [29]. Melting curve analysis was conducted to 
confirm the specificity of PCR amplifications. Comparative ∆∆Ct method was used for 
quantification of gene expression using the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene as the reference for data normalization [17].  
2.6. Statistical analysis
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All data were subjected to statistical analysis using Student’s t test and GraphPad Prism 5 
(GraphPad Software, La Jolla, CA). Each data point represented mean ± standard error 
from 2-3 independent experiments. The results were considered statistically, if P < 0.05. 
 
3. RESULTS 
 
3.1. Induction of AvBD9 gene expression by HDAC inhibitors 
We showed recently that butyrate upregulates several chicken HDPs and enhances 
resistance of chicken against S. enteritidis [27]. Since butyrate is a well-known HDAC 
inhibitor, we evaluated the ability of several HDAC inhibitors (Fig. 1A) to stimulate 
AvBD9 synthesis. We treated chicken HD11 macrophages and primary monocytes with 
different concentrations of a few selected HDAC inhibitors for 24 h, followed by RNA 
isolation and real-time RT-PCR analysis of the AvBD9 gene expression.  As expected, 
TSA, SAHA, sodium valproate, CAY10433, and CAY10398, all stimulated AvBD9 gene 
expression significantly in a dose-dependent manner both in HD11 cells (Fig. 1B) and 
primary monocytes (Fig. 1C), albeit at lower magnitudes than butyrate, which peaked 
with an approximately 2,000-fold AvBD9 induction in HD11 cells and greater than 250-
fold induction in primary monocytes. On the other hand, all other HDAC inhibitors 
showed a similar efficacy in inducing AvBD9 expression in HD11 cells with an 
approximately 100-fold maximum induction (Fig. 1B). In primary monocytes, valproate 
and SAHA led to 100-fold increase in AvBD9 expression, but TSA, CAY10433, and 
CAY10398 showed a reduced efficiency, with approximately 10-, 30-, and 6-fold 
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maximum increase, respectively (Fig. 1C). The results collectively are suggestive of a 
beneficial role of histone hyperacetylation in AvBD9 gene induction. The variation in the 
magnitude of AvBD9 gene regulation among different HDAC inhibitors could be due to 
their relative potency in HDAC inhibition in different cell types.  
3.2. Suppression of butyrate-induced AvBD9 gene expression by HAT inhibitors 
Acetylation of nucleosomal core histones is achieved by either activation of HATs or 
inhibition of HDACs [22, 23, 25]. If hyperacetylation of histones through HDAC 
inhibition promotes the AvBD9 gene expression, inhibition of the HAT activity will have 
an opposite effect. To confirm the effect of HAT inhibition on butyrate-induced AvBD9 
expression, we pretreated HD11 cells with different concentrations of HAT inhibitors for 
2 h prior to stimulation with 1 mM butyrate for another 24 h. Cells were then harvested 
and subjected to total RNA extraction and real time RT-PCR. As expected, EGCG dose-
dependently reversed the induction of the AvBD9 gene by butyrate (Fig. 2A). EGCG at 
200 µM suppressed butyrate-induced AvBD9 expression by 15-fold. Anacardic acid (Fig. 
2B) or garcinol (Fig. 2C) also similarly inhibited AvBD9 gene induction caused by 
butyrate, although with a less efficacy. The stronger inhibitory effect of EGCG than that 
of anacardic acid or garcinol on the HAT activity is likely to be attributed to the fact that 
EGCG inhibits a broader spectrum of HATs than other two HAT inhibitors [30-33]. It is 
noted that, due to a low expression level of AvBD9 under the basal condition, a further 
decrease by HAT inhibitors could not be reliably detected in HD11 cells. Nevertheless, 
these studies reinforced a critical role of histone acetylation in regulation of the AvBD9 
gene. 
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3.3. Involvement of p38 MAPK and JNK pathways in AvBD9 gene expression  
MAPK signaling was shown to be involved in butyrate-mediated LL-37 induction in 
human intestinal epithelial cells and lung epithelial cells [19, 34, 35]. To determine the 
effect of three classical MAPK pathways on AvBD9 gene expression, we pretreated 
HD11 cells with or without p38 MAPK, ERK1/2, and JNK inhibitors for 1 h, followed by 
incubation with butyrate for another 24 h. Real-time RT-PCR analysis of AvBD9 
expression revealed that SB203580 and SP600125, p38 MAPK and JNK inhibitors, 
respectively, significantly attenuated butyrate-mediated AvBD9 induction (Fig. 3). On 
the other hand, PD, a specific ERK1/2 inhibitor, failed to suppress AvBD9 expression 
induced by butyrate. These results suggested that p38 MAPK and JNK, but not ERK1/2, 
pathways are involved in butyrate-triggered AvBD9 expression. 
3.4. Impact of cAMP signaling on AvBD9 synthesis 
In addition to histone acetylation and MAPK signaling, cAMP analogs and adenylate 
cyclase agonists were shown to induce LL37 expression in human intestinal epithelial 
cells [26]. To study whether cAMP signaling is also involved in the regulation of HDP 
synthesis in chickens, we first treated HD11 cells with different concentrations of two 
cAMP analogs, 8-bromo-cAMP and DB-cAMP for up to 48 h. As shown in Fig. 4, the 
two analogs triggered both a time- and dose-dependent induction of AvBD9 gene 
expression. Treatment with 0.5 mM 8-bromo-cAMP led to an approximately 5-fold 
increase in AvBD9 expression at 24 h and 15-fold AvBD9 induction at 48 h (Fig. 4A). 
More strikingly, DB-cAMP caused a much more pronounced augmentation of AvBD9 
gene expression, with approximately 200-, 500-, and 1,000-fold induction following
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stimulation with 2 mM of DB-cAMP for 6, 12, and 24 h, respectively (Fig. 4B). The 
results clearly confirmed the role of cAMP in the HDP induction in the chicken. The 
marked difference in AvBD9 regulation between two cAMP analogs are likely due to the 
release of two butyrate molecules from the cAMP motif after DB-cAMP is taken up into 
the cells. Therefore, unlike 8-bromo-cAMP, the effect seen with DB-cAMP is likely due 
to the combined actions of both butyrate and cAMP. In fact, a growing body of evidence 
suggested a consideration of the biological effect of butyrate when DB-cAMP is used as a 
cAMP analog [36-39]. Nevertheless, it is beneficial to use DB-cAMP to enhance host 
immunity and disease resistance by taking advantage of the HDP-inducing activity of 
both butyrate and cAMP motifs existing in DB-cAMP.  
In addition to cAMP analogs, we further examined the AvBD9-inducing efficacy 
of adenylate cyclase agonists, which promote the endogenous synthesis of cAMP. As 
shown in Fig. 5, 10 µM forskolin stimulated AvBD9 gene expression in a time-dependent 
fashion peaking significantly with nearly a 9-fold induction at 24 h, consistent with the 
potency of a cAMP analog, 8-bromo-cAMP. Similarly, CT at 0.5 µg/ml also exerted a 
statistically significant 6-fold increase in AvBD9 gene expression following 24 h 
stimulation, whereas PT caused a marginal 2-fold enhancement at 12 or 24 h (Fig. 5) 
demonstrated negligible induction of AvBD9 at and 24h time period. Overall, these data 
indicated that, in addition to cAMP itself, any agent that stimulates the synthesis of 
cAMP is also capable of promoting AvBD9 gene expression in the chicken. 
3.5. Synergistic induction of AvBD9 gene expression by HDAC inhibitors and 
adenylate cyclase agonists
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Since both HDAC inhibitors and cAMP signaling activators induce AvBD9 gene 
expression, we sought to test whether there is a synergistic interaction between these two 
groups of agents. To our surprise, we observed a clear, statistically significant synergy 
between butyrate and three different adenylate cyclase agonists. Stimulation of HD11 
cells with 1 or 2 mM butyrate for 24 h led to 200- to 800-fold increase in AvBD9 gene 
expression, whereas forskolin gave a maximum, less than 10-fold induction (Fig. 6A). 
However, a nearly 3,000-fold increase in AvBD9 expression was observed in HD11 cells 
in response to a combination of both 2 mM butyrate and 5 µM forskolin, which reflected 
an additional 3-fold increase over butyrate alone (Fig. 6A). Similarly, CT or PT led to a 
marginal increase in AvBD9 gene expression in HD11 cells; however, simultaneous 
treatment with butyrate and CT or PT resulted in an additional 3- to 4-fold increase over 
butyrate alone (Fig. 6B and 6C). The results revealed a clear synergistic interaction 
between histone deacetylation and cAMP signaling.  
It is worth noting that forskolin regulated butyrate-mediated AvBD9 expression in 
a biphasic manner, with higher concentrations from 10 to 200 µM suppressing AvBD9 
induction (Fig. 6A). The same is true with forskolin alone, with low concentrations 
inducing gene expression and high concentrations causing a dose-dependent abrogation 
of AvBD9 induction (Fig. 6A, insert). These results perhaps are not surprising, given the 
existence of negative feedback mechanisms in cAMP signaling. In fact, prolonged 
production of cAMP negatively regulates the expression of LL-37 in human intestinal 
cells, due to the presence of an inducible cAMP early repressor in the LL-37 gene 
promoter [26]. It is likely that such a similar cAMP repressor is also present in the 
AvBD9 gene promoter; however, it needs to be experimentally confirmed.
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4. DISCUSSION 
 
HDAC inhibitors including butyrate, sulforaphane, phenylbutyrate, and TSA were found 
to induce the HDP expression in humans [[19-21, 34, 35]]. We also revealed the role of 
butyrate on regulation of several HDP gene expression in chickens [27]. Here, we 
revealed for the first time that several additional HDAC inhibitors such as sodium 
valproate, SAHA, CAY10433, and CAY10398 are all capable of stimulating AvBD9 
gene expression in chicken HD11 macrophage cells and primary monocytes, albeit with 
different efficacies. Furthermore, we showed that HAT inhibitors suppressed the HDP 
gene expression. The results made it evident that HDP regulation by histone 
deacetylation is conserved in both mammals and aves. However, it is likely that 
differences exist among species and/or cell types. For example, phenylbutyrate was 
shown to be more potent than butyrate in inducing LL-37 expression in human HT29 
intestinal cells [21]. Sulforaphane also exhibited higher efficiency than butyrate in 
triggering human β-defensin 2 (HBD-2) expression in the same cell line [20]. However, 
when compared to butyrate, phenylbutyrate had a less stimulating effect on AvBD9 
expression in chicken HD11 cells while sulforaphane had no effect (data shown). 
Therefore, it is prudent to confirm the HDP-inducing efficacy of individual HDAC 
inhibitors in each species. 
 cAMP activates gene expression through protein kinase A (PKA)-mediated 
phosphorylation of intracellular transcription factors such as cAMP response element-
binding protein (CREB), which in turn promotes recruitment of several HATs including 
113 
CREB binding protein (CBP) and p300 to the target gene promoter, leading to chromatin 
remodeling and gene transactivation [40]. HDAC inhibitors act to prolong CREB 
phosphorylation, thereby potentiating CBP/p300 recruitment and cAMP-dependent gene 
transcription [41] . Therefore, it is not surprising to see a clear synergy between adenylate 
cyclase agonists and HDAC inhibitors in triggering AvBD9 gene expression. It will be 
important to explore such a synergistic interaction between cAMP signaling and histone 
deacetylation in boosting HDP synthesis, host immunity, and disease resistance.  
 We have also shown JNK and p38 MAPK signaling pathways are critically 
important in regulating butyrate-mediated AvBD9 gene induction, which is consistent 
with an earlier report on the existence on the AvBD9 (also known as gallinacin-6) 
promoter region of several binding sites for activator protein 1 (AP-1) [42], which is a 
common target transcription factor activated by MAP kinases [43].  It is intriguing to 
note that ERK1/2 MAPK pathway appears not to be involved in regulating AvBD9 
expression in HD11 cells. However, both ERK1/2 and JNK, but not p38 MAP kinase 
pathways are implicated in LL-37 induction in human lung and intestinal epithelial cells 
stimulated with butyrate [19, 35] or phenylbutyrate [21]. The reason for such a 
discrepancy between humans and chickens remains unknown. It is plausible that species- 
or gene-specific regulatory pattern of HDP expression may exist.  
 Taken together, our results clearly showed that histone deacetylation, cAMP 
signaling, and MAP kinase pathways are involved in AvBD9 gene regulation. All these 
three events are likely to cooperate with each other in providing a fine tuning of the 
AvBD9 expression. HDAC inhibitors enhance histone acetylation and relax the AvBD9 
gene promoter, achieving two benefits simultaneously. First, it prolongs cAMP signaling 
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resulting in enhanced recruitment of CREB to the AvBD9 promoter. Secondly, it 
facilitates binding of AP-1 activated by MAP kinases to the gene promoter. It is also 
known that cAMP and MAPK signaling pathways cross-talks in that cAMP-dependent 
activation of PKA ultimately activates all three classical MAP kinase pathways [26]. 
 Because of many desirable host defense roles of HDPs, further exploration of the 
regulatory mechanisms of HDPs will facilitate development of strategies for optimal 
production of HDPs, which will have enormous implications in boosting host immunity 
and disease resistance without resorting to conventional antibiotics. 
 
ACKNOWLEDGEMENTS 
 
This work was supported by a USDA NIFA grant (2008-35204-04544) and Oklahoma 
Agricultural Experiment Station project H-2811.  
 
                                                      REFERENCES 
 
1.  Steinstraesser, L., Kraneburg, U., Jacobsen, F. & Al-Benna, S. (2011) Host defense 
peptides and their antimicrobial-immunomodulatory duality, Immunobiology. 216, 322-
33. 
2.  Yeung, A. T. Y., Gellatly, S. L. & Hancock, R. E. W. (2011) Multifunctional cationic 
host defence peptides and their clinical applications, Cellular and Molecular Life 
Sciences. 68, 2161-2176. 
115  
3.  Peters, B. M., Shirtliff, M. E. & Jabra-Rizk, M. A. (2010) Antimicrobial peptides: 
primeval molecules or future drugs?, PLoS Pathog. 6, e1001067. 
4.  Lai, Y. & Gallo, R. L. (2009) AMPed up immunity: how antimicrobial peptides have 
multiple roles in immune defense, Trends Immunol. 30, 131-41. 
5.  Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms, Nature. 415, 
389-95. 
6.  Brogden, K. A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in 
bacteria?, Nat Rev Microbiol. 3, 238-50. 
7.  Tecle, T., Tripathi, S. & Hartshorn, K. L. (2010) Review: Defensins and cathelicidins 
in lung immunity, Innate Immun. 16, 151-9. 
8.  Sang, Y. & Blecha, F. (2008) Antimicrobial peptides and bacteriocins: alternatives to 
traditional antibiotics, Anim Health Res Rev. 9, 227-35. 
9.  Hancock, R. E. & Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new 
anti-infective therapeutic strategies, Nat Biotechnol. 24, 1551-7. 
10.  Bevins, C. L. & Salzman, N. H. (2011) Paneth cells, antimicrobial peptides and 
maintenance of intestinal homeostasis, Nat Rev Microbiol. 9, 356-68. 
11.  Ganz, T. (2003) Defensins: antimicrobial peptides of innate immunity, Nature 
Reviews Immunology. 3, 710-720. 
12.  Lehrer, R. I. (2004) Primate defensins, Nature Reviews Microbiology. 2, 727-738. 
13.  Selsted, M. E. & Ouellette, A. J. (2005) Mammalian defensins in the antimicrobial 
immune response, Nature Immunology. 6, 551-557. 
14.  Zanetti, M. (2004) Cathelicidins, multifunctional peptides of the innate immunity, J 
Leukoc Biol. 75, 39-48.  
116 
15.  Lynn, D. J., Higgs, R., Gaines, S., Tierney, J., James, T., Lloyd, A. T., Fares, M. A., 
Mulcahy, G. & O'Farrelly, C. (2004) Bioinformatic discovery and initial characterisation 
of nine novel antimicrobial peptide genes in the chicken, Immunogenetics. 56, 170-7. 
16.  van Dijk, A., Veldhuizen, E. J., van Asten, A. J. & Haagsman, H. P. (2005) 
CMAP27, a novel chicken cathelicidin-like antimicrobial protein, Vet Immunol 
Immunopathol. 106, 321-7. 
17.  Xiao, Y., Cai, Y., Bommineni, Y. R., Fernando, S. C., Prakash, O., Gilliland, S. E. & 
Zhang, G. (2006) Identification and functional characterization of three chicken 
cathelicidins with potent antimicrobial activity, J Biol Chem. 281, 2858-67. 
18.  Goitsuka, R., Chen, C. L., Benyon, L., Asano, Y., Kitamura, D. & Cooper, M. D. 
(2007) Chicken cathelicidin-B1, an antimicrobial guardian at the mucosal M cell 
gateway, Proc Natl Acad Sci U S A. 104, 15063-8. 
19.  Schauber, J., Iffland, K., Frisch, S., Kudlich, T., Schmausser, B., Eck, M., Menzel, 
T., Gostner, A., Luhrs, H. & Scheppach, W. (2004) Histone-deacetylase inhibitors induce 
the cathelicidin LL-37 in gastrointestinal cells, Mol Immunol. 41, 847-54. 
20.  Schwab, M., Reynders, V., Loitsch, S., Steinhilber, D., Schroder, O. & Stein, J. 
(2008) The dietary histone deacetylase inhibitor sulforaphane induces human beta-
defensin-2 in intestinal epithelial cells, Immunology. 125, 241-51. 
21.  Steinmann, J., Halldorsson, S., Agerberth, B. & Gudmundsson, G. H. (2009) 
Phenylbutyrate induces antimicrobial peptide expression, Antimicrob Agents Chemother. 
53, 5127-33. 
22.  Dokmanovic, M., Clarke, C. & Marks, P. A. (2007) Histone deacetylase inhibitors: 
overview and persepctives, Mol Cancer Res. 5, 981-9.  
117 
23.  Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms, 
Genes Dev. 12, 599-606. 
24.  Ho, E. & Dashwood, R. H. (2010) Dietary manipulation of histone structure and 
function, World Rev Nutr Diet. 101, 95-102. 
25.  Santini, V., Gozzini, A. & Ferrari, G. (2007) Histone deacetylase inhibitors: 
molecular and biological activity as a premise to clinical application, Curr Drug Metab. 
8, 383-93. 
26.  Chakraborty, K., Maity, P. C., Sil, A. K., Takeda, Y. & Das, S. (2009) cAMP 
stringently regulates human cathelicidin antimicrobial peptide expression in the mucosal 
epithelial cells by activating cAMP-response element-binding protein, AP-1, and 
inducible cAMP early repressor, J Biol Chem. 284, 21810-27. 
27.  Sunkara, L. T., Achanta, M., Schreiber, N. B., Bommineni, Y. R., Dai, G., Jiang, W., 
Lamont, S., Lillehoj, H. S., Beker, A., Teeter, R. G. & Zhang, G. (2011) Butyrate 
enhances disease resistance of chickens by inducing antimicrobial host defense peptide 
gene expression, PLoS One (In Press). 
28.  Beug, H., von Kirchbach, A., Doderlein, G., Conscience, J. F. & Graf, T. (1979) 
Chicken hematopoietic cells transformed by seven strains of defective avian leukemia 
viruses display three distinct phenotypes of differentiation, Cell. 18, 375-90. 
29.  Xiao, Y., Hughes, A. L., Ando, J., Matsuda, Y., Cheng, J. F., Skinner-Noble, D. & 
Zhang, G. (2004) A genome-wide screen identifies a single beta-defensin gene cluster in 
the chicken: implications for the origin and evolution of mammalian defensins, BMC 
Genomics. 5, 56. 
118 
30. Sun, Y., Jiang, X., Chen, S. & Price, B. D. (2006) Inhibition of histone 
acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation, 
FEBS Lett. 580, 4353-6. 
31.  Balasubramanyam, K., Altaf, M., Varier, R. A., Swaminathan, V., Ravindran, A., 
Sadhale, P. P. & Kundu, T. K. (2004) Polyisoprenylated benzophenone, garcinol, a 
natural histone acetyltransferase inhibitor, represses chromatin transcription and alters 
global gene expression, J Biol Chem. 279, 33716-26. 
32.  Choi, K. C., Jung, M. G., Lee, Y. H., Yoon, J. C., Kwon, S. H., Kang, H. B., Kim, 
M. J., Cha, J. H., Kim, Y. J., Jun, W. J., Lee, J. M. & Yoon, H. G. (2009) 
Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B 
lymphocyte transformation via suppression of RelA acetylation, Cancer Res. 69, 583-92. 
33.  Balasubramanyam, K., Swaminathan, V., Ranganathan, A. & Kundu, T. K. (2003) 
Small molecule modulators of histone acetyltransferase p300, J Biol Chem. 278, 19134-
40. 
34.  Schauber, J., Svanholm, C., Termen, S., Iffland, K., Menzel, T., Scheppach, W., 
Melcher, R., Agerberth, B., Luhrs, H. & Gudmundsson, G. H. (2003) Expression of the 
cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of 
signalling pathways, Gut. 52, 735-41. 
35.  Kida, Y., Shimizu, T. & Kuwano, K. (2006) Sodium butyrate up-regulates 
cathelicidin gene expression via activator protein-1 and histone acetylation at the 
promoter region in a human lung epithelial cell line, EBC-1, Mol Immunol. 43, 1972-81. 
36.  Swislocki, N. I. (1970) Decomposition of dibutyryl cyclic AMP in aqueous buffers, 
Anal Biochem. 38, 260-9. 
119 
37.  Barker, H. & Isles, T. E. (1978) Actions of cyclic AMP, its butyryl derivatives and 
Na butyrate on the HCG output of malignant trophoblast cells in vitro, Br J Cancer. 38, 
158-62. 
38.  Bruce, J. H., Ramirez, A., Lin, L. & Agarwal, R. P. (1992) Effects of cyclic AMP 
and butyrate on cell cycle, DNA, RNA, and purine synthesis of cultured astrocytes, 
Neurochem Res. 17, 315-20. 
39.  Prasad, K. N. & Gilmer, K. N. (1974) Demonstration of dopamine-sensitive 
adenylate cyclase in malignant neuroblastoma cells and change in sensitivity of adenylate 
cyclase to catecholamines in "differentiated" cells, Proc Natl Acad Sci U S A. 71, 2525-9. 
40.  Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H. & Nakatani, Y. (1996) 
The transcriptional coactivators p300 and CBP are histone acetyltransferases, Cell. 87, 
953-9. 
41.  Michael, L. F., Asahara, H., Shulman, A. I., Kraus, W. L. & Montminy, M. (2000) 
The phosphorylation status of a cyclic AMP-responsive activator is modulated via a 
chromatin-dependent mechanism, Molecular and cellular biology. 20, 1596-603. 
42.  van Dijk, A., Veldhuizen, E. J., Kalkhove, S. I., Tjeerdsma-van Bokhoven, J. L., 
Romijn, R. A. & Haagsman, H. P. (2007) The beta-defensin gallinacin-6 is expressed in 
the chicken digestive tract and has antimicrobial activity against food-borne pathogens, 
Antimicrob Agents Chemother. 51, 912-22. 
43.  Whitmarsh, A. J. & Davis, R. J. (1996) Transcription factor AP-1 regulation by 
mitogen-activated protein kinase signal transduction pathways, J Mol Med (Berl). 74, 
589-607. 
  
120  
FIGURE AND FIGURE LEGENDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
4
16
64
256
1024
4096
Av
B
D9
 
Fo
ld
 
In
cr
ea
se
1
4
16
64
256
1024
Av
BD
9 
Fo
ld
 
In
cr
ea
se
B
C
Butyrate
(mM)
Valproate
(mM)
SAHA
(µM)
TSA
(µM)
CAY10433
(µM)
CAY10398
(µM)
0.
5 1 2 4 1 2 4 8
1.
25 2.
5 5
0.
12
5
0.
25 25 50 10
0 25 50 10
0
0.
5 1 2 4 1 2 4 8
1.
25 2.
5 5
0.
12
5
0.
25 25 50 10
0 25 50 10
0
***
**
***
***
*
**
***
**
**
*
**
*
**
***
***
*
***
***
***
*
***
***
***
*
***
***
***
***
**
**
***
***
***
***
***
** **
**
B
TSA (Trichostatin A)
A
SAHA
(suberoylanilide hydroxamic acid)
CAY10398 CAY10433 / BML-210
Sodium Valproate Sodium Butyrate
121 
Fig. 1. Induction of AvBD9 gene expression by histone deacetylase inhibitors. 
Different concentrations of histone deacetylase inhibitors (A) were incubated in duplicate 
with chicken HD11 macrophages (B) or primary monocytes (C) with for 24 h, followed 
by real-time RT-PCR analysis of AvBD9 expression. Each bar represents mean ± 
standard error of the data from 2-4 independent experiments. *P < 0.05, ** P < 0.001, 
and *** P < 0.0001 by unpaired Student’s t-test as compared to the untreated control. 
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Fig. 2. Suppression of butyrate-mediated AvBD9 gene induction by histone 
acetyltransferase inhibitors. Chicken HD11 cells were treated in duplicate with 
indicated concentrations of epigallocatechin gallate (EGCG) (A), anacardic acid (B) and 
garcinol (C) for 2 h before treatment with 1 mM butyrate for another 24 h. Real-time RT-
PCR analysis was carried out to evaluate AvBD9 gene expression. Each bar shows mean 
± standard error of the data from 3-4 experiments.*P < 0.05, ** P < 0.001, and *** P < 
0.0001 by unpaired Student’s t-test.  
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Fig. 3. Role of p38 and JNK mitogen-activated protein kinase pathways on AvBD9 
gene induction. Chicken HD11 cells were incubated in duplicate with 25 µM p38 
inhibitor (SB203580), 20 µM JNK inhibitor (SP600125) or 50 µM MEK inhibitor 
(PD98059) for 1 h, followed by stimulation with 4 mM butyrate for another 24 h. AvBD9 
expression was evaluated with real-time RT-PCR. Data from 2-4 experiments are 
presented in bars showing means ± standard error. ***P ≤ 0.0001 by unpaired Student’s 
t-test. 
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Fig. 4. Upregulation of AvBD9 gene expression by cAMP analogs. Chicken HD11 
cells were treated in duplicate with different concentrations of 8-bromo-cAMP (A) and 
dibutyryl-cAMP (B) for 6, 12 or 24 h. Real-time RT-PCR analysis was performed to 
evaluate AvBD9 gene expression and the results were normalized against GAPDH. Each 
bar shows mean ± standard error of the data from 2-3 experiments. 
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Fig. 5. Induction of AvBD9 gene expression by adenylate cyclase agonists. Chicken 
HD11 cells were stimulated with 10 µM forskolin, 0.5 µg/ml cholera toxin, or 0.5 µg/ml 
pertussis toxin for 6, 12 or 24 h. AvBD9 gene expression was analyzed by real-time RT-
PCR, and relative fold change was calculated as compared to the negative control. Values 
represent means ± standard error of the data from 2 to 3 experiments. *P < 0.05, and ** P 
< 0.001 by unpaired Student’s t-test.  
 
  
0
2
4
6
8
10
12
Time (h)   0   6  12  24      0   6  12  24      0   6  12  24
Forskolin     Cholera Toxin   Pertussis Toxin
Fo
ld
 
ch
an
ge
**
*
126 
 
 
 
 
 
  
 
Fig. 6. Synergistic increase in AvBD9 gene expression by butyrate and adenylate 
cyclase agonists. HD11 cells were pretreated in duplicate for 1 h with different 
concentration of forskolin (FSK (µM): (            ) :  0,1, 2, 5, 10, 20, 50, 100, and 200) (A) 
or cholera toxin (CT; µg/ml) (B), followed by 2 mM butyrate for another 24 h. Similarly, 
different concentrations of pertussis toxin (PT; µg/ml) (C) were added to HD 11 cells for 
1 h prior to 1 mM butyrate incubation for another 24 h. Real-time RT-PCR analysis was 
used to evaluate AvBD9 gene expression, and the relative fold change was quantitated 
using 2-∆∆Ct method. Each bar demonstrates means ± standard error of the data from 2 to 3 
experiments. The effect of FSK alone on AvBD9 induction was shown in the insert, panel 
A. *P < 0.05, ** P < 0.001, and *** P < 0.0001 by unpaired Student’s t-test as compared 
to the cells treated with butyrate alone. 
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Scope and Method of Study: Routine use of antibiotics for growth promotion and disease 
prevention in animal agriculture has caused the concern for rapid emergence of 
antimicrobial resistance in public health worldwide. In this study, we attempted 
an antibiotic-alternative approach to disease control and prevention by enhancing 
host defense peptide (HDP) synthesis and animal immunity. We evaluated a 
diverse group of dietary supplements for their capacity to stimulate chicken HDP 
gene expression in vitro and in vivo by real-time RT-PCR. Chicken infection 
studies were further conducted to confirm an enhanced resistance to Salmonella 
enteritidis following oral supplementation of selected dietary factors. We also 
evaluated the role of histone acetylation as well as cAMP and MAP kinase 
signaling in the transcriptional regulation of HDP synthesis in chicken HD11 
macrophage cells. 
 
Findings and Conclusions: Butyrate, a short-chain fatty acid and a well-known histone 
deacetylase inhibitor, enhances a large set of chicken HDPs and confers resistance 
to S. enteritidis. In addition, the induction of chicken HDP synthesis is largely 
inversely correlated with the aliphatic carbon chain length of free fatty acids, with 
short-chain fatty acids being the most potent, medium-chain fatty acids moderate, 
and long-chain fatty acids mostly ineffective. Desirably, free fatty acids enhance 
HDP expression with a minimum impact on proinflammatory response. 
Additionally, a combination of three short-chain fatty acids, namely acetate, 
propionate, and butyrate, induced HDP expression in a synergistic manner, 
leading to more significant reduction of the S. enteritidis load in the chicken than 
individual fatty acids. Moreover, cAMP signaling agonists stimulated chicken 
HDP gene expression and synergized with butyrate in HDP induction. We 
confirmed that p38 and JNK, but not ERK1/2, MAP kinase signaling pathways 
are involved in butyrate-mediated chicken HDP induction. Identification of potent 
HDP-inducing dietary supplements and a better understanding of transcriptional 
regulatory mechanisms of HDP gene expression will undoubtedly facilitate 
development of antibiotic-free approaches to disease control and prevention with 
applications in both animal and public health. 
